UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended ~~September~~ 30March 31, ~~2022~~2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from to

Commission File No. 001-37704

DarioHealth Corp.

(Exact name of registrant as specified in its charter)

Delaware	45-2973162
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)


18 W. 18th St.
New York, New York	10011
(Address of Principal Executive Offices)	(Zip Code)

(972)-4 770-6377

(Registrant’s telephone number, including area code)

n/a

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of exchange on which registered
Common Stock, par value $0.0001 per share	DRIO	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐	Large accelerated filer	☐	Accelerated filer
☒	Non-accelerated filer	☒	Smaller reporting company
		☐	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November~~May ~~11, 2022,~~8, 2023, the registrant had ~~23,296,754~~26,361,307 shares of common stock outstanding.

When used in this quarterly report, the terms “DarioHealth,” “the Company,” “we,” “our,” and “us” refer to DarioHealth Corp., a Delaware corporation, our subsidiaries LabStyle Innovation Ltd. ~~and Upright Technologies Ltd.~~, ~~each of which are~~an Israeli ~~companies, and Upright Technologies Inc. and~~company, PsyInnovations Inc., ~~each~~ a Delaware ~~company.~~company, and DarioHealth India Services Pvt. Ltd., an Indian company.. “Dario” is registered as a trademark in the United States, Israel, China, Canada, Hong Kong, South Africa, Japan, Costa Rica and Panama. “DarioHealth” is registered as a trademark in the United States and Israel.

Table of Contents

DarioHealth Corp.

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

		Page

Cautionary Note Regarding Forward-Looking Statements		3

PART 1- FINANCIAL INFORMATION

Item 1.	Interim Consolidated Financial Statements (unaudited)	F-1

	Interim Consolidated Balance Sheets	F-2 – F-3

	Interim Consolidated Statements of Comprehensive Loss	F-4

	Interim Statements of Stockholders’ Equity	F-5 ~~– F- 6~~

	Interim Consolidated Statements of Cash Flows	~~F-7~~F-6

	Notes to Interim Consolidated Financial Statements	~~F-8~~F-7 – ~~F-25~~F-28

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4

Item 4.	Control and Procedures	11

PART II- OTHER INFORMATION		12

Item 1A.	Risk Factors	12

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	12

Item 6.	Exhibits	13

SIGNATURES		14

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

●

our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise;

●

our product launches and market penetration plans;

●

the execution of agreements with various providers for our solution;

●

our ability to maintain our relationships with key partners, including Sanofi U.S. Services Inc. (“Sanofi”) ;

●

our ability to complete required clinical trials of our product and obtain clearance or approval from the United States Food and Drug Administration (the “FDA”), or other regulatory agencies in different jurisdictions;

●

our ability to maintain or protect the validity of our U.S. and other patents and other intellectual property;

●

our ability to retain key executive members;

●

our ability to internally develop new inventions and intellectual property;

●

the impact of the COVID-19 pandemic on our manufacturing, sales, business plan and the global economy;

●

interpretations of current laws and the passages of future laws; and

●

acceptance of our business model by investors.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements ~~are described~~may be found under the ~~heading “Risk Factors” in Part I, Item 1A.,~~section of our Annual Report on Form 10-K for the ~~fiscal~~ year ended December 31, ~~2021 (the “2021 Annual Report”) and in Part II, Item 1A., of our Quarterly Report~~2022 (filed on ~~Form 10-Q for the quarter ended June 30, 2022 (the “Quarterly Report”),~~March 9, 2022) entitled “Risk Factors” as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF ~~SEPTEMBER 30, 2022~~MARCH 31, 2023

UNAUDITED

INDEX

		Page
Interim Consolidated Balance Sheets		F-2 – F-3

Interim Consolidated Statements of Comprehensive Loss		F-4

Interim Statements of Stockholders’ Equity		F-5 ~~– F-~~ 6

Interim Consolidated Statements of Cash Flows		F-76

Notes to Interim Consolidated Financial Statements		F-87 – F-2528

F-1

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

September 30,

December 31,


2022

2021

Unaudited



ASSETS

CURRENT ASSETS:





Cash and cash equivalents

$
57,081

$
35,808

Short-term restricted bank deposits

176

192

Trade receivables

4,521

1,310

Inventories

7,762

6,228

Other accounts receivable and prepaid expenses

2,042

2,067

Total current assets

71,582

45,605

NON-CURRENT ASSETS:

Deposits

6

20

Operating lease right of use assets

1,174

287

Long-term assets

21

57

Property and equipment, net

858

702

Intangible assets, net

11,053

12,460

Goodwill

41,640

41,640

Total non-current assets

54,752

55,166

Total assets

$
126,334

$
100,771


	March 31,		December 31,
	2023		2022
	Unaudited
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	38,789	$	49,357
Short-term investments		4,304		-
Short-term restricted bank deposits		225		165
Trade receivables		2,797		6,416
Inventories		6,877		7,956
Other accounts receivable and prepaid expenses		2,484		1,630

Total current assets		55,476		65,524

NON-CURRENT ASSETS:
Deposits		6		6
Operating lease right of use assets		1,170		1,206
Long-term assets		149		111
Property and equipment, net		765		788
Intangible assets, net		8,803		9,916
Goodwill		41,640		41,640

Total non-current assets		52,533		53,667

Total assets	$	108,009	$	119,191

The accompanying notes are an integral part of the unaudited interim consolidated financial statements.

F-2

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except stock and stock data)


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
	Unaudited				Unaudited
LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Trade payables	$	1,982	$	5,109	$	1,883	$	2,322
Deferred revenues		990		1,195		925		1,320
Operating lease liabilities		270		266		291		293
Other accounts payable and accrued expenses		6,512		7,806		5,935		6,592
Earn-out liability		1,770		825
Loan, current						8,583		8,823

Total current liabilities		11,524		15,201		17,617		19,350

NON-CURRENT LIABILITIES
Operating lease liabilities		817		21		751		827
Long-term loan		24,046		—		16,745		18,105
Warrant liability		1,001		—		830		910
Other long-term liabilities						36		—

Total non-current liabilities		25,864		21		18,362		19,842

STOCKHOLDERS’ EQUITY
Common stock of $0.0001 par value - Authorized: 160,000,000 shares at September 30, 2022 (unaudited) and December 31, 2021; Issued and Outstanding: 23,291,008 and 16,573,420 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively		2		2
Preferred stock of $0.0001 par value - Authorized: 5,000,000 shares at September 30, 2022 (unaudited) and December 31, 2021; Issued and Outstanding: 9,912 and 11,927 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively		*) -		*) -
Common stock of $0.0001 par value - Authorized: 160,000,000 shares; Issued and Outstanding: 25,875,295 and 25,724,470 shares at March 31, 2023 and December 31, 2022, respectively						3		3
Preferred stock of $0.0001 par value - Authorized: 5,000,000 shares; Issued and Outstanding: 3,557 and 3,567 shares at March 31, 2023 and December 31, 2022, respectively						*) -		*) -
Additional paid-in capital		361,912		307,561		370,702		365,846
Accumulated deficit		(272,968)		(222,014)		(298,675)		(285,850)

Total stockholders’ equity		88,946		85,549		72,030		79,999

Total liabilities and stockholders’ equity	$	126,334	$	100,771	$	108,009	$	119,191

*) - Represents an amount lower than $1

The accompanying notes are an integral part of the unaudited interim consolidated financial statements.

F-3

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except stock and stock data)


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
	2022		2021		2022		2021		2023		2022

	Unaudited				Unaudited				Unaudited
Revenues:
Services	$	4,552	$	776	$	12,802	$	1,852	$	5,257	$	4,984
Hardware and consumable products		2,053		4,853		8,045		12,633
Consumer hardware										1,809		3,075
Total revenues		6,605		5,629		20,847		14,485		7,066		8,059

Cost of revenues:
Services*		1,826		126		3,538		233
Hardware and consumable products*		1,874		3,433		7,255		8,498
Services										1,477		452
Consumer hardware										1,340		2,689
Amortization of acquired intangible assets		1,105		1,244		3,131		2,339		1,081		932
Total cost of revenues		4,805		4,803		13,924		11,070		3,898		4,074

Gross profit		1,800		826		6,923		3,415		3,168		3,985

Operating expenses:
Research and development	$	4,803	$	5,506	$	14,867	$	11,903	$	5,165	$	5,927
Sales and marketing		7,571		10,696		26,403		27,476		6,340		9,535
General and administrative		3,999		7,123		13,453		18,865		4,071		4,395

Total operating expenses		16,373		23,325		54,723		58,244		15,576		19,857

Operating loss		14,573		22,499		47,800		54,829		12,408		15,872

Total financial (income) expenses, net		1,059		(55)		1,775		346

Loss before taxes		15,632		22,444		49,575		55,175

Income Tax		—		—		1		—
Total financial expenses, net										417		44

Net loss	$	15,632	$	22,444	$	49,576	$	55,175	$	12,825	$	15,916

Other comprehensive income (loss):
Other comprehensive loss:
Deemed dividend	$	494	$	488	$	1,378	$	1,520	$	-	$	451

Net loss attributable to shareholders	$	16,126	$	22,932	$	50,954	$	56,695	$	12,825	$	16,367

Net loss per share:

Basic and diluted loss per share	$	0.64	$	1.18	$	2.03	$	2.98
Basic and diluted loss per share of common stock									$	0.45	$	0.74
Weighted average number of common stock used in computing basic and diluted net loss per share		22,973,197		16,473,449		22,876,397		16,202,541		27,570,013		19,624,079

* Excluding amortization

The accompanying notes are an integral part of the unaudited interim consolidated financial statements.

F-4

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)


							Additional				Total								Additional				Total
	Common Stock			Preferred Stock			paid-in		Accumulated		stockholders’		Common Stock			Preferred Stock			paid-in		Accumulated		stockholders’
Three Months Ended September 30, 2022	Number	Amount		Number	Amount		capital		deficit		equity
Balance as of June 30, 2022 (unaudited)	22,860,044	$	2	10,797	$	*)-	$	356,492	$	(256,842)	$	99,652
Three Months Ended March 31, 2023													Number	Amount		Number	Amount		capital		deficit		equity
Balance as of December 31, 2022(audited)													25,724,470	$	3	3,567	$	*)-	$	365,846	$	(285,850)	$	79,999

Issuance of common stock to directors and employees	5,564		*)-	—		—		29		—		29
Issuance of common stock to consultants and service provider	8,941		*)-	—		—		43		—		43
Conversion of preferred stock to common stock	308,711		*)-	(885)		*)-		—		—		*)-	3,582		*)-	(10)		*)-		—		—		*)-
Deemed dividend related to issuance of preferred stock	—		—	—		—		494		(494)		—
Issuance of warrants to service providers	—		—	—		—		609		—		609	—		—	—		—		630		—		630
Stock-based compensation	107,748		*)-	—		—		4,245		—		4,245	147,243		*)-	—		—		4,226		—		4,226
Net loss	—		—	—		—		—		(15,632)		(15,632)	—		—	—		—		—		(12,825)		(12,825)

Balance as of September 30, 2022 (unaudited)	23,291,008	$	2	9,912	$	*)-	$	361,912	$	(272,968)	$	88,946
Balance as of March 31, 2023 (unaudited)													25,875,295	$	3	3,557	$	*)-	$	370,702	$	(298,675)	$	72,030

							Additional				Total								Additional				Total
	Common Stock			Preferred Stock			paid-in		Accumulated		stockholders’		Common Stock			Preferred Stock			paid-in		Accumulated		stockholders’
Nine Months Ended September 30, 2022	Number	Amount		Number	Amount		capital		deficit		equity
Three Months Ended March 31, 2022													Number	Amount		Number	Amount		capital		deficit		equity
Balance as of December 31, 2021(audited)	16,573,420	$	2	11,927	$	*)-	$	307,561	$	(222,014)	$	85,549	16,573,420	$	2	11,927	$	*)-	$	307,561	$	(222,014)	$	85,549

Exercise of warrants	81,221		*)-	—		—		—		—		*)-	81,221		*)-	—		—		—		—		*)-
Issuance of common stock to directors and employees	29,755		*)-	—		—		190		—		190
Issuance of common stock to consultants and service provider	21,901		*)-	—		—		230		—		230
Conversion of preferred stock to common stock	648,128		*)-	(2,015)		—		—		—		*)-	316,052		*)-	(1,030)		—		—		—		*)-
Deemed dividend related to issuance of preferred stock	—		—	—		—		1,378		(1,378)		—	—		—	—		—		451		(451)		—
Issuance of warrants to service providers	—		—	—		—		2,467		—		2,467	—		—	—		—		1,301		—		1,301
Stock-based compensation	1,064,126		*)-	—		—		11,011		—		11,011	169,156		*)-	—		—		4,042		—		4,042
Issuance of common stock and pre-funded warrants, net of issuance cost	4,674,454		*)-	—		—		38,023		—		38,023	4,674,454		*)-	—		—		38,023		—		38,023
Issuance of common stock, net of issuance cost upon Acquisition of Physimax Technologies Ltd.	256,660		*)-	—		—		1,186		—		1,186	256,660		*)-	—		—		1,186		—		1,186
Repurchase and retirement of common stock	(58,657)		*)-	—		—		(134)		—		(134)
Net loss	—		—	—		—		—		(49,576)		(49,576)	—		—	—		—		—		(15,916)		(15,916)

Balance as of September 30, 2022 (unaudited)	23,291,008	$	2	9,912	$	*)-	$	361,912	$	(272,968)	$	88,946
Balance as of March 31, 2022 (unaudited)													22,070,963	$	2	10,897	$	*)-	$	352,564	$	(238,381)	$	114,185

*) Represents an amount lower than $1.

The accompanying notes are an integral part of the unaudited interim consolidated financial statements.

F-5

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

INTERIM CONSOLIDATED STATEMENTS OF ~~STOCKHOLDERS’ EQUITY~~~~(UNAUDITED)~~CASH FLOWS

U.S. dollars in thousands ~~(except stock and stock data)~~

Additional

Total

Common Stock

Preferred Stock

paid-in

Accumulated

stockholders’
Three Months Ended September 30, 2021

Number

Amount

Number

Amount

capital

deficit

equity
Balance as of June 30, 2021 (unaudited)

16,330,842

$
*)-

12,122

$
*)-

$
295,124

$
(177,011)

$
118,113

Payment for executives and directors under Stock for Salary Program

1,791

*)-

—

—

34

—

34
Issuance of common stock to consultants and service provider

112,332

*)-

—

—

1,705

—

1,705
Issuance of common stock to directors and employees

18,885

*)-

—

—

303

303
Conversion of preferred stock to common stock

8,100

*)-

(25)

*)-

—

—

*)-
Deemed dividend related to issuance of preferred stock

—

—

—

—

488

(488)

—
Issuance of warrants to service providers

—

—

—

—

2,121

—

2,121
Stock-based compensation

37,394

*)-

—

—

4,607

—

4,607
Net loss

—

—

—

—

—

(22,444)

(22,444)

Balance as of September 30, 2021 (unaudited)

16,509,344

$
*)-

12,097

$
*)-

$
304,382

$
(199,943)

$
104,439

Additional

Total

Common Stock

Preferred Stock

paid-in

Accumulated

stockholders’
Nine Months Ended September 30, 2021

Number

Amount

Number

Amount

capital

deficit

equity
Balance as of December 31, 2020 (audited)

8,119,493

$
*)-

15,823

$
*)-

$
171,399

$
(143,248)

$
28,151

Payment for executives and directors under Stock for Salary Program

9,124

*)-

—

—

133

—

133
Exercise of options

40,545

*)-

—

—

256

—

256
Exercise of placement agent warrants

111,061

*)-

—

—

—

—

*)-
Exercise of warrants

219,992

*)-

—

—

633

—

633
Issuance of common stock to consultants and service provider

287,753

*)-

—

—

4,078

—

4,078
Issuance of common stock to directors and employees

18,885

*)-

—

—

303

—

303
Conversion of preferred stock to common stock

874,530

*)-

(3,726)

*)-

—

—

*)-
Deemed dividend related to issuance of preferred stock

—

—

—

—

1,520

(1,520)

—
Issuance of warrants to service providers

—

—

—

—

4,918

—

4,918
Stock-based compensation

1,093,537

*)-

—

—

9,238

—

9,238
Issuance of common stock, net of issuance cost

3,278,688

*)-

—

—

64,877

—

64,877
Issuance of common stock upon acquisition of Upright Technologies Ltd.

1,687,612

*)-

—

—

28,933

—

28,933
Issuance of common stock upon acquisition of PsyInnovations Inc.(dba WayForward)

768,124

*)-

—

—

18,094

—

18,094
Net loss

—

—

—

—

—

(55,175)

(55,175)

Balance as of September 30, 2021 (unaudited)

16,509,344

$
*)-

12,097

$
*)-

$
304,382

$
(199,943)

$
104,439

*) Represents an amount lower than $1.

~~The accompanying notes are an integral part of the unaudited interim consolidated financial statements~~

~~F-6~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~U.S. dollars in thousands~~


	Nine months ended				Three months ended
	September 30,				March 31,
	2022		2021		2023		2022

	Unaudited				Unaudited
Cash flows from operating activities:
Net loss	$	(49,576)	$	(55,175)	$	(12,825)	$	(15,916)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation, common stock, and payment in stock to directors, employees, consultants, and service providers		13,898		18,670		4,856		5,343
Depreciation		243		202		97		70
Change in operating lease right of use assets		(887)		137		36		7
Amortization of acquired intangible assets and inventories step-up		3,224		3,381
Increase in trade receivables		(3,211)		(1,125)
Decrease in other accounts receivable, prepaid expense and long-term assets		129		221
Increase in inventories		(1,534)		96
Increase in trade payables		(3,136)		-
Amortization of acquired intangible assets						1,113		963
Decrease (increase) in trade receivables						3,619		(3,264)
Increase in other accounts receivable, prepaid expense and long-term assets						(892)		(1,550)
Decrease (increase) in inventories						1,079		(1,555)
Decrease in trade payables						(439)		(890)
Decrease in other accounts payable and accrued expenses		(1,401)		(1,368)		(621)		(721)
Decrease in deferred revenues		(205)		(139)		(395)		(102)
Change in operating lease liabilities		800		(173)		(78)		(27)
Remeasurement of earn-out		945		-		-		(452)
Non-Cash financial expenses		807		-
Non-Cash financial income						(307)		-

Net cash used in operating activities		(39,904)		(35,273)		(4,757)		(18,094)

Cash flows from investing activities:
Investment In deposit		-		(2)
Purchase of property and equipment		(399)		(193)		(74)		(66)
Cash paid as part of PsyInnovations Inc. (dba WayForward) acquisition		-		(5,023)
Purchase of short-term investments						(4,996)		-
Proceeds from redemption of short-term investments						708		-
Cash paid as part of Upright Technologies Ltd. acquisition		-		(2,472)		-		(115)
Purchase of intangible assets		(115)		-

Net cash used in investing activities		(514)		(7,690)		(4,362)		(181)

Cash flows from financing activities:
Proceeds from issuance of common stock and prefunded warrants (net of issuance costs)		38,023		64,877		-		38,023
Proceeds from exercise of warrants		-		633
Proceeds from exercise of options		-		256
Proceeds from borrowings on credit agreement		23,786		-
Repurchase and retirement of common stock		(134)		-
Principal payments on long-term loan						(1,389)		-

Net cash provided by financing activities		61,675		65,766		(1,389)		38,023

Increase in cash, cash equivalents and restricted cash and cash equivalents		21,257		22,803		(10,508)		19,748
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period		35,948		28,725		49,470		35,948

Cash, cash equivalents and restricted cash and cash equivalents at end of period	$	57,205	$	51,528	$	38,962	$	55,696
Supplemental disclosure of cash flow information:
Cash paid during the period for interest on long-term loan	$	969	$	-	$	1,072	$	-
Non-cash activities:
Right-of-use assets obtained in exchange for lease liabilities	$	1,177	$	80	$	28	$	58

The accompanying notes are an integral part of the unaudited interim consolidated financial statements.

~~F-7~~F-6

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 1: - GENERAL

DarioHealth Corp. (the “Company” ~~or “DarioHealth”~~) was incorporated in Delaware and commenced operations on August 11, 2011.

DarioHealth is a Global Digital Therapeutics (DTx) company ~~changing the way people with chronic conditions manage their health. By~~ delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching, DarioHealth has developed an approach ~~that empowers~~with the intent to empower individuals to adjust their lifestyle in holistic way.

DarioHealth’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Our diabetes solution, its user-centric approach is used by tens of thousands of customers around the globe. DarioHealth is rapidly expanding its solutions for additional chronic conditions such as hypertension and moving into new geographic markets.

DarioHealth’s digital therapeutic platform has been designed with a ‘user-first’ strategy, focusing on the user’s needs first and foremost, and user experience and satisfaction. User satisfaction is constantly measured and drives, all company processes, including our technology design.

The Company ~~operates as~~has one reporting unit and one operating segment.

The Company has a wholly owned subsidiary, LabStyle Innovation Ltd. (“LabStyle”), which was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company’s intellectual property and to perform research and development, manufacturing, marketing and other business activities.

Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, short-term deposits, restricted deposits, short-term investments and trade receivables. For cash and cash equivalents, the Company is exposed to credit risks in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.

For trade receivables, the Company is exposed to credit risk in the event of non-payment by customers to the extent of the amounts recorded on the accompanying consolidated balance sheets.

As of ~~September 30, 2022,~~March 31, 2023, the Company's two major customers accounted for ~~39.3%~~44.4% and ~~30.3%~~13.1%, respectively, of the Company's accounts receivable balance.

The Company's two major customers accounted for ~~26.9%~~42.2% and ~~20.7%~~10.0%, respectively, for the three months period ended ~~September 30, 2022, and 8.5% and 35.2%, respectively, for the nine-months period ended September 30, 2022,~~March 31, 2023, of the Company's ~~revenue in the relevant periods.~~revenue.

On January 26, 2021, the Company entered into a share purchase agreement ~~(the “Share Purchase Agreement”)~~ pursuant to which the Company, through LabStyle, acquired all of the outstanding securities of Upright Technologies Ltd. and its wholly owned subsidiary Upright Technologies Inc. (“Upright”). Upright is a digital musculoskeletal (“MSK”) health company focused on preventing and treating the most common MSK conditions through behavioral science, biofeedback, coaching, and wearable tech.

~~F-8~~F-7

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 1: - GENERAL (Cont.)

On May 15, 2021, the Company entered into an agreement and plan of merger pursuant to which the Company, through its wholly owned subsidiary WF Merger Sub, Inc. (“Merger Sub”), merged with PsyInnovations Inc. (“WayForward”), pursuant to which the Merger Sub was the surviving company. WayForward is a mental health company that developed the WayForward behavioral digital health platform with artificial intelligence enabled screening to triage and navigate members to specific interventions, digital cognitive behavioral therapy, self-directed care, expert coaching and access to in-person and telehealth provider visits.

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the Company incurred operating losses and negative cash flows from operating activities amounting to ~~$47,800~~$12,408 and $~~39,904~~,$4,757, respectively. On ~~September 30, 2022, we~~March 31, 2023, the Company had ~~$57,081~~$43,093 in available cash and cash ~~equivalents.~~equivalents and short-term investments. Management believes that the Company’s cash on hand isand short-term investments are sufficient to meet its obligations as they come due for at least a period of twelve months from the date of the issuance of these interim condensed consolidated financial statements. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of its product offering.

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim consolidated financial statements as of ~~September 30, 2022,~~March 31, 2023, have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s consolidated financial position as of ~~September 30, 2022,~~March 31, 2023, and the Company’s consolidated results of operations and the Company’s consolidated cash flows for the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023. Results for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, ~~2022.~~2023. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022.

Use of Estimates

Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. These estimates are based on management's knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.

~~F-9~~F-8

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Significant Accounting Policies

a. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021~~2022 are applied consistently in these unaudited interim consolidated financial statements.

b. Short-term restricted bank deposits:

The following table provides a reconciliation of the cash balances reported on the balance sheets and the cash, cash equivalents, and short-term restricted bank deposits balances reported in the statements of cash flows:


	September 30,		September 30,		March 31,		March 31,
	2022		2021		2023		2022
	Unaudited		Unaudited		Unaudited		Unaudited
Cash, and cash equivalents as reported on the balance sheets	$	57,081	$	51,331	$	38,789	$	55,558
Short-term restricted bank deposits, as reported on the balance sheets		124		197		173		138

Cash, restricted cash, cash equivalents and restricted cash and cash equivalents as reported in the statements of cash flows	$	57,205	$	51,528
Cash, restricted cash, cash equivalents, and restricted cash and cash equivalents as reported in the statements of cash flows					$	38,962	$	55,696

c. Short-term investments:

The Company's short-term investments consist of investments in a fund with readily determinable fair value. The Company's investment is carried at fair value, with changes in fair value recognized in the Statements of Comprehensive Loss.

d. Revenue recognition

The Company recognizes revenue in accordance with ASC 606, “Revenue from contracts with customers,” when (or as) it satisfies performance obligations by transferring promised products or services to its customers in an amount that reflects the consideration the Company expects to receive. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

F-9

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

c.NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Consumers revenue

The Company considers customer and distributor purchase orders to be contracts with a customer. For each contract, the Company considers the promise to transfer tangible products and/or services, each of which are distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to rebates and adjustments to determine the net consideration to which the Company expects to receive. As the Company’s standard payment terms are less than one year, the contracts have no significant financing component. The Company allocates the transaction price to each distinct performance obligation based on their relative standalone selling price. Revenue from tangible products is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs at shipment. The revenues from fixed-price services are recognized ratably over the contract period and the costs associated with these contracts are recognized as incurred.

Commercial revenue

The Company provides a mobile and web-based digital therapeutics health management programs to employers and health plans for their employees or covered individuals. Such programs include live clinical coaching, content, automated journeys, hardware, and lifestyle coaching, currently supporting diabetes, prediabetes and obesity, hypertension, behavioral health (BH) and musculoskeletal health (MSK). At contract inception, the Company assesses the type of services being provided and assesses the performance obligations in the contract. These solutions integrate access to the Company’s web-based platform, and clinical and data services to provide an overall health management solution. The promises to transfer these goods and services are not separately identifiable and is considered a single continuous service comprised of a series of distinct services that are substantially the same and have the same pattern of transfer (i.e., distinct days of service). These services are consumed as they are received, and the Company recognizes revenue each month using the variable consideration allocation. Revenue is recognized either on a per engaged member per month (PEMPM) or a per employee per month (PEPM) basis. Contracts typically have a duration of more than one year.

Certain of the Company’s contracts include client performance guarantees and a portion of the fees in those contracts are subject to performance-based metrics such as clinical outcomes or minimum member utilization rate. The Company includes in the transaction price some or all of an amount of variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Refunds to a customer that results from performance levels that were not met by the end of the measurement period are adjusted to the transaction price, and therefore estimated at the outset of the arrangement.

The Company has also entered into contracts (Note 5) with a preferred partner and a health plan provider in which the Company provides data license, development and implementation services.

F-10

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)

e. Business and Asset Acquisitions

When the Company acquires a business, the purchase price is allocated to the tangible and identifiable intangible assets, net of liabilities assumed. Any residual purchase price is recorded as goodwill. The allocation of the purchase price requires management to make significant estimates in determining the fair values of assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates can include, but are not limited to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital. These estimates are inherently uncertain and unpredictable. During the measurement period, which may be up to one year from the acquisition date, adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed may be recorded, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.

The Company accounts for a transaction as an asset acquisition when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, or otherwise does not meet the definition of a business. Asset acquisition-related costs are capitalized as part of the asset or assets acquired.

~~F-10~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. dollars in thousands (except stock and stock data)~~

~~NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)~~

d.f. . Recently ~~issued accounting pronouncements, not yet adopted:~~Adopted Accounting Pronouncements

(i)

In ~~September~~June 2016, the Financial Accounting Standards Board ~~(the “FASB”~~(“FASB”) issued Accounting Standards Update (“ASU”) ~~No.~~ 2016-13, ~~“Financial~~Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial ~~Instruments”~~Instruments (“ASU 2016-13”). ASU 2016-13 ~~changes~~amends the impairment model ~~for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required~~ to ~~use a new forward-looking “expected loss” model that generally~~utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the ~~earlier~~more timely recognition of ~~allowances for losses. The guidance also requires increased disclosures. For the Company, the amendments in the update were originally~~losses, with an effective date for the first quarter of fiscal ~~years beginning after December 15, 2019, including the interim periods within those fiscal years.~~year 2020. In November 2019, the FASB issued ASU No. 2019-10 which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined by the ~~SEC)~~U.S. Securities and Exchange Commission) and other non-SEC reporting entities to fiscal years beginning after December 15, 2022, including ~~the~~ interim periods within those fiscal periods. ~~Early adoption is permitted.~~ The Company ~~is currently assessing~~adopted the standard effective as of January 1, 2023, and the adoption of this standard did not have an impact on the ~~guidance will have on its~~Company's consolidated financial statements.

2.(ii)

In August 2020, the FASB issued ASU 2020-06, ~~(“ASU 2020-06”)~~“Debt - Debt with Conversion and Other Options (subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (subtopic 815-40), ~~which simplifies~~” The new standard reduces the ~~guidance on the issuer’s~~number of accounting models in ASC 470-20 that require separate accounting for ~~convertible debt instruments by removing the separation models for (a) convertible debt with a cash~~non-bifurcated embedded conversion ~~feature and (b) convertible instruments with a beneficial conversion feature.~~features. As a result, ~~entities~~convertible instruments will no longer be subject to the cash conversion features model or to the beneficial conversion features model and be accounted for as a single unit of account as long as no other features require bifurcation and recognition as derivatives The Company adopted ASU 2020-06, effective January 1, 2023, using the modified retrospective method. The prior period consolidated financial statements have not ~~separately present~~been retrospectively adjusted and continue to be reported under the accounting standards in ~~equity an embedded conversion feature in such debt. Instead, they will account~~effect for ~~a convertible debt instrument wholly as debt, unless certain other conditions are met.~~those periods. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ~~ASU 2020-06. ASU 2020-06 also requires that~~this standard did not have a material impact on the effect of potential share settlement be included in the diluted earnings per share calculation when an instrument may be settled in cash or share. This amendment removes current guidance that allows an entity to rebut this presumption if it has a history or policy of cash settlement. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, the treasury stock method will be no longer available. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2023, with early adoption permitted for fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, which requires companies to apply Accounting Standards Codification 606 (“ASC 606”) to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. This creates an exception to the general recognition and measurement principle in Accounting Standards Codification 805 (“ASC 805”). requires companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. For the Company, the guidance is effective for fiscal years beginning after December 15, 2022 andCompany's interim ~~periods within those fiscal years. The Company is currently evaluating the impact of ASU 2021-08 on its~~condensed consolidated financial statements.

F-11

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 3: – ACQUISITIONS

Prior Acquisitions

Technology Purchase of Physimax Technologies Ltd.

On March 31, 2022, ~~(the “Acquisition Date”),~~ the Company completed the acquisition, through its subsidiary LabStyle, of a technology from Physimax Technologies Ltd (“Physimax Technology”). The Company considered this transaction as an asset acquisition.

The consideration transferred included ~~the issuance of~~ 256,660 shares of ~~its~~ common stock, ~~subjected to certain terms of~~ ~~lock-up periods~~ ~~valued at $1,186,~~and a cash payment of $500, ~~of which $400 was paid during the fourth quarter of 2021, and the remaining to be paid on the second quarter of 2022,~~ The total consideration transferred in the acquisition of Physimax Technology was $1,686. In addition, the Company incurred acquisition-related costs in anthe amount of $131.

Purchase price allocation:

Under asset acquisition accounting principles, the total purchase price was allocated to Physimax Technology as set forth below.

NOTE 4: - INVENTORIES


	September 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
	Unaudited				Unaudited
Raw materials	$	1,339	$	714	$	1,152	$	1,346
Finished products		6,423		5,514		5,725		6,610

	$	7,762	$	6,228	$	6,877	$	7,956

During the ~~nine-month~~three-month period ended ~~September 30, 2022,~~March 31, 2023, and the year ended December 31, ~~2021,~~2022, total inventory write-down expenses amounted to ~~$22~~$38 and ~~$73,~~$88, respectively.

F-12

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 5: - REVENUES

The Company is operating a multi-condition healthcare business, empowering individuals to manage their chronic conditions and take steps to improve their overall health. The Company generates revenue directly from individuals through a la carte offering and membership plans. The Company also contracts with enterprise business market groups to provide digital therapeutics solutions for individuals to receive access to services through the Company’s commercial arrangements.

Agreement with Preferred Partner

On February 28, 2022, the Company entered into an exclusive preferred partner, co-promotion, development ~~collaboration~~ and license agreement for a term of five (5) years (the “Exclusive Agreement”). Pursuant to the Exclusive Agreement, the Company will provide a license to access and use certain Company data. In addition, the Company may provide development services for new products of the other party.

~~The Company has determined that the other party is a customer.~~

The aggregate consideration under the contract is up to $30 million over the initial term of the Exclusive Agreement, consisting of (i) an upfront payment, (ii) ~~annual compensation~~payments for development ~~costs~~services per ~~annual~~ development ~~plans~~plan to be agreed upon annually and (iii) certain contingent milestone payments upon meeting certain net sales and enrollment rate milestones at any time during the term of the Exclusive Agreement.

~~During~~

Since the second quarter of 2022, the parties' joint steering committee approved the first-year development plan, pursuant to the terms of the Exclusive Agreement. The Company has concluded that the development plan is a contract modification which should be accounted for as a separate contract. The Company has also concluded that the development plan includes a single performance obligation – to provide development services, which is satisfied over time. The contract consideration includes ~~fixed and~~ variable ~~consideration. As~~consideration, as of ~~September 30, 2022,~~March 31, 2023, the Company excluded the variable payments from the transaction price since it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is ~~resolved.~~resolve.

During 2022, the first development plan was approved and completed. The Company ~~has also~~ concluded that the ~~measure of progress that best depicts~~first development plan should be accounted for as a separate contract. As such, for the ~~Company's performance~~year ended December 31, 2022, the Company recognized $4,000 in ~~transferring control~~revenues for the completion of the first development plan.

On December 13, 2022, the second development plan was approved by the parties. The Company concluded that the second development plan should be accounted for as a separate contract which includes development services ~~transferred to the customer is an input method,~~performance obligations, satisfied over time, based on labor ~~hours consumed. During~~hours. As such, for the year ended December 31, 2022, the Company recognized $1,506 in revenues, and for the three months ended ~~September 30, 2022,~~March 31, 2023, the Company ~~has~~ recognized $1,485 in revenues, ~~under~~and with additional revenues from the second development plan of ~~$1,370 with additional revenues of $655~~$1,009 expected to be recognized by the end of ~~2022.~~June 2023.

Agreement with National Health Plan

On October 1, 2021, the Company entered into a Master Service Agreement (“MSA”) and into a statement of work (“SOW”, and such SOW, the “October SOW”) with a national health plan (“Health Plan”). ~~Pursuant to the terms of the MSA, the Company will perform services as set forth in each statement of work (each “SOW”).~~

~~On October 1, 2021, the Company entered into an SOW (“October SOW”) with the Health Plan.~~ Pursuant to the October SOW, the Company will provide the Health Plan access to web and app-based platform, for behavioral health.

The Company has concluded that the ~~MSA and the October SOW should be combined into~~contract contained a single performance obligation – to provide access to the Company's platform. The consideration in the contract ~~(the “Contract”~~was based entirely on customer usage.

OnAugust 2022, the Company entered into an additional SOW (“August SOW”). with the Health Plan according to which the Company will provide implementation service and shall develop additional features to be included in the platform.

F-13

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 5: - REVENUES (Cont.)

The Company has concluded that the Contract contained a single performance obligation – to provide access to the Company's platform. The consideration in the Contract was based entirely on customer usage. Since no usage has occurred as of September 30, 2022, the Company has yet to recognize any revenues from the October SOW.

On~~August 2022, the Company entered into an additional SOW (“August SOW”) with the Health Plan, and as a result, the Company will provide additional services to the Health Plan.~~

~~The Company~~ concluded that the August SOW ~~is a contract modification, which~~ should be accounted for as a separate ~~contract which includes~~contract. The Company has concluded that the August SOW contained two performance obligations as follows:

~~(i)~~~~Phase 1 – Digital Behavioral Health Navigation Platform Implementation. This performance obligation includes configuration and implementation of the platform.~~

~~(ii)~~Phase 2 – Enhancements to the Digital Behavioral Health Navigation Platform. This performance obligation includes adding additional features and capabilities to the Platform, such as user chat, additional sorting questions and linking to the Health Plan’s additional services.

(i)

Digital Behavioral Health Navigation Platform Implementation. This performance obligation includes configuration and implementation of the platform.

(ii)

Enhancements to the Digital Behavioral Health Navigation Platform. This performance obligation includes adding additional features and capabilities to the Platform.

The August SOW includes a fixed consideration in the amount of $2,650. The Company allocated the consideration between the two performance obligations based on standalone selling prices. The Company determined the standalone selling prices based on the expected cost plus a margin approach.

~~As of September 30,~~

For the year ended December 31, 2022, the Company ~~has~~ recognized revenues of ~~$1,778 with~~$1,778. For the three months ended March 31, 2023, the Company recognized $707 in revenues and additional revenues of ~~$872~~$255 expected to be recognized by June of 2023.

Revenue Source:

The following tables represent the Company’s total revenues for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023, and 2022 ~~and 2021~~ disaggregated by revenue source:


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
	2022		2021		2022		2021		2023		2022

	Unaudited				Unaudited				Unaudited
Commercial	$	4,195	$	309	$	11,591	$	491	$	4,950	$	4,549
Consumers		2,410		5,320		9,256		13,994		2,116		3,510

	$	6,605	$	5,629	$	20,847	$	14,485	$	7,066	$	8,059

Deferred Revenue

The Company recognizes contract liabilities, or deferred revenues, when it receives advance payments from customers ~~before performance obligations primarily related services have been performed. Advance payments are received at~~prior to the ~~beginning~~satisfaction of the ~~service period and the related deferred revenues are reclassified to revenue ratably over the service period.~~Company's performance obligations. The balance of deferred revenues approximates the aggregate amount of the transaction price allocated to the unsatisfied performance obligations at the end of the reporting period.

F-14

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 5: - REVENUES (Cont.)

The following table presents the significant changes in the deferred revenue balance during the ~~nine~~three months ended ~~September 30, 202~~2:March 31, 2023:


Balance, beginning of the period	$	1,195	$	1,320
New performance obligations		5,754		7,066
Reclassification to revenue as a result of satisfying performance obligations		(5,959)		(7,461)

Balance, end of the period	$	990	$	925

~~Because all performance obligations in the Company’s contracts with customers relate~~

Costs to ~~contracts with~~Fulfill a ~~duration of less than one year, the Company has~~ ~~elected~~ to apply the optional exemption and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.Contract

The Company defer costs incurred to fulfill contracts that: (1) relate directly to the contract; (2) are expected to generate resources that will be used to satisfy our performance obligation under the contract; and (3) are expected to be recovered through revenue generated under the contract. Contract fulfillment costs are expensed as we satisfy our performance obligations and recorded in cost of revenue.

Costs to fulfill a contract are recorded to other accounts receivable and prepaid expenses and long term assets.

Costs to fulfill a contract consist of (1) deferred consumer hardware cost incurred in connection with delivery of services that are deferred. (2) deferred costs incurred, related to future performance obligations which are capitalized.

Costs to fulfill a contract as of March 31, 2023, and December 31, 2022 consisted of the following:


	March 31,		December 31,
	2023		2022
	Unaudited
Costs to fulfill a contract, current	$	396	$	483
Costs to fulfill a contract, noncurrent		79		41

Total Costs to fulfill a contract	$	475	$	524

Costs to fulfill a contract were as follows:


		Costs to
		fulfill a contract

Beginning balance as of December 31, 2022	$	524
Additions		263
Cost of revenue recognized		(312)

Ending balance as of March 31, 2023		475

F-15

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 6: - FAIR VALUE MEASUREMENTS

Under U.S. GAAP, fair value is defined as the amount that would be received for selling an asset or paid to transfer a liability in an orderly transaction between market participants and requires that assets and liabilities carried at fair value are classified and disclosed in the following three categories:



Level 1- 1 -		~~Unadjusted~~Valuations based on quoted prices in active markets for identical assets ~~or liabilities accessible~~that the Company has the ability to ~~the reporting entity at measurement date.~~access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

Level 2 -

Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 2-3 -

~~Other than quoted prices included in Level 1~~Valuations based on inputs that are ~~observable for~~unobservable and significant to the ~~asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.~~

~~Level 3~~

~~Unobservable inputs for the asset or liability used to measure~~overall fair value ~~to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.~~

The carrying amounts of cash and cash equivalents, short-term and restricted bank deposits, trade receivables, trade payables, other receivables and prepaid expenses and other payables and accrued expenses approximate their fair value due to the short-term maturity of such instruments.measurement.

The availability of observable inputs can vary from instrument to instrument and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment, and the investments are categorized as Level 3.

The carrying amounts of cash and cash equivalents, short-term restricted bank deposits, trade receivables, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company's Loan Facility (as defined herein), and warrant liability were measured at fair value using Level 3 unobservable inputs until the resolutiondate of March 31, 2023.

~~F-15~~F-16

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 6: - FAIR VALUE MEASUREMENTS (Cont.)

The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:


	September 30, 2022								March 31, 2023
	Unaudited								Unaudited
	Fair Value		Level 1		Level 2		Level 3		Fair Value		Level 1		Level 2		Level 3

			(in thousands)								(in thousands)
Financial Assets:
Financial commitment asset (“FCA”)	$	454	$	—	$	—	$	454
Short-term investments									$	4,304	$	4,304	$	—	$	0

Total Financial Assets	$	454	$	—	$	—	$	454	$	4,304	$	4,304	$	—	$	0

Financial Liabilities:
Earn out liability	$	1,770	$	—	$	—	$	1,770
Long Term Loan		24,046		—		—		24,046		25,328		—		—		25,328
Warrant liability		1,001		—		—		1,001		830		—		—		830

Total Financial Liabilities	$	26,817	$	—	$	—	$	26,817	$	26,156	$	—	$	—	$	26,156


	December 31, 2021								December 31, 2022
	Fair Value		Level 1		Level 2		Level 3		Fair Value		Level 1		Level 2		Level 3

			(in thousands)								(in thousands)
Financial Liabilities:
Earn out liability	$	825	$	—	$	—	$	825
Long Term Loan										26,928		—		—		26,928
Warrant liability									$	910		—		—		910

Total Financial Liabilities	$	825	$	—	$	—	$	825	$	27,838	$	—	$	—	$	27,838

~~FCA~~Loan Facility

On June 9, 2022, the Company entered into a Credit Agreement (the “Credit Agreement”), by and between the Company, as borrower, and OrbiMed Royalty and Credit Opportunities III, LP, as the lender (the “Lender”). The Credit Agreement provides for a ~~five-year~~five-year senior secured credit facility in an aggregate principal amount of up to $50 million (the “Loan Facility” or “Loan”), of which $25 million was made available on the ~~Closing Date~~closing date (the “Initial Commitment Amount” or "First Tranche") and up to $25 million may be made available on or prior to June 30, 2023, subject to certain revenue requirements (the “Delayed Draw Commitment Amount” or “Second Tranche”). On June 9, 2022, the Company closed on the Initial Commitment Amount, less certain fees and expenses payable to or on behalf of the Lender.

The FCA instrument was recognized in connection with the Delayed Draw Commitment Amount (Note 7). The fair value of the FCA is estimated by the Company at each reporting date, which are prepared based on significant inputs that are generally determined based on relative value analyses. The FCA fair value was estimated using a discount rate of 15.6% which reflects the internal rate of return of the Loan at closing of the transactions contemplated by the Credit Agreement as of June 9, 2022and represents the $25 million Delayed Draw Commitment Amount that may be made available on or prior to June 30, 2023 on similar terms to the Initial Commitment Amount. Therefore, the value of the FCA for the Delayed Draw Commitment Amount of the Loan was initially estimated as 50% of the sum of the commitment fee paid upfront and the lender expenses in relation to the Loan origination.

~~F-16~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. dollars in thousands (except stock and stock data)~~

~~NOTE 6: - FAIR VALUE MEASUREMENTS~~ ~~(Cont.)~~

~~The fair value of the FCA is amortized over the period of the Delayed Draw Commitment Amount on a straight-line basis. The total amount was estimated at $454.~~

~~Earn out Liability~~

As part of the acquisition of Wayforward on June 7, 2021, the consideration transferred included earn-out payable in up to 237,076 restricted shares of Common Stock. The earn-out arrangement is not indexed to the Company's own stock and was accounted as a liability~~and subsequently measured at fair value through earnings until the settlement date of December 31, 2022.~~

On July 7, 2022, the Company entered into an Amendment to Agreement and Plan of Merger (the “Amendment”) with representatives of the former equity holders of PsyInnovations, Inc. Pursuant to the terms of the Amendment, the Company agreed to reduce the earn-out threshold of revenue derived from Wayforward products from $5 million to $3 million.

In determining the earn-out fair value, the Company used the Monte-Carlo simulation valuation technique, in order to predict the probability of different outcomes that rely on repeated random variables.

~~The significant inputs into the models were:~~

September 30,

December 31,

2022

2021
Expected Term (in years)

0.33

1.08
Expected Volatility

32.1%

32.1%
Beta

45%

45%
Debt Rate

4.62%

0.82%

~~For the nine months ended September 30, 2022, the Company recorded expenses from remeasurement of the earn-out in the amount of $945.~~

~~Loan Facility~~

The fair value of the Loan Facility is recognized in connection with the Company’s Credit Agreement with respect to the Initial Commitment Amount only (Note 7). The fair value of the Loan Facility was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the Loan, which is reported within non-current liabilities and current liabilities (Maturity Date - June 9, 2027) on the consolidated balance sheets, is estimated by the Company at each reporting date based on significant inputs that are generally determined based on relative value analyses.

F-17

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 6: - FAIR VALUE MEASUREMENTS (Cont.)

The Loan incorporates comparisons to instruments with similar covenants, collateral, and risk profiles and was obtained using a discounted cash flow technique. On the date of Loan origination, or June 9, 2022, the discount rate was arrived at by calibrating the loan amount of $25 million with the fair value of the warrants of ~~$1,930~~$830 and the loan terms interest rate of secured overnight financing rate (“SOFR”) + 9.5%. The implied internal rate of return of the loan was 15.6%. The fair value of the Loan, as of ~~September 30,~~March 31, 2023, and December 31, 2022, ~~was~~were estimated using a discount rate of 15.6% which reflects the internal rate of return of the Loan at closing, as of June 9, 2022. The change in the fair value of the loan was recorded in earnings since the Company has concluded that no adjustment related to instrument specific credit risk was required.

~~F-17~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. dollars in thousands (except stock and stock data)~~

~~NOTE 6: - FAIR VALUE MEASUREMENTS~~ ~~(Cont.)~~

Warrant Liability

The fair value of the warrant liability is recognized in connection with the Company’s Loan agreement with the Lender and with respect to the Initial Commitment Amount only (Note 7). The fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the warrant liability, which is reported within non-current liabilities on the consolidated balance sheets, is estimated by the Company based on the Monte-Carlo simulation valuation technique, in order to predict the probability of different outcomes that rely on repeated random variables.

The fair value of the warrant liability was estimated using a Monte-Carlo simulation valuation technique, with the following significant unobservable inputs (Level 3):


		June 9,		September 30,		March 31,		December 31,
		2022		2022		2023		2022
Stock price	$	7.45	$	4.63	$	4.12	$	4.28
Exercise price		6.62		6.62		6.62		6.62
Expected term (in years)		7.00		6.69		6.19		6.44
Volatility		148.8%		146.8%		150.3%		148.1%
Dividend rate		-		-		-		-
Risk-free interest rate		3.13%		4.05%		3.57%		4.05%

The following tables present the summary of the changes in the fair value of our Level 3 financial instruments:

Three months ended September 30, 2022

Unaudited

Long-Term Loan

Warrant Liability

FCA
Balance as of June 30, 2022

$
23,061

$
1,588

$
607
Change in fair value

985

(587)

(153)

Balance as of September 30, 2022

$
24,046

$
1,001

$
454


	Nine months ended September 30, 2022						Three months ended
	Unaudited						March 31, 2023
		Long-Term Loan		Warrant Liability		FCA		Long-Term Loan		Warrant Liability
Balance as of January 1, 2022	$	—	$	—	$	—
Issuance		23,070		1,930		—
Initial measurement of the FCA		—		—		607
Balance as of January 1, 2023							$	26,928	$	910
Principal payments on long-term loan								(1,389)		—
Change in fair value		976		(929)		(153)		(211)		(80)

Balance as of September 30, 2022	$	24,046	$	1,001	$	454
Balance as of March 31, 2023							$	25,328	$	830

F-18

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

~~F-18~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. dollars in thousands (except stock and stock data)~~

NOTE 7: -~~LONG TERM~~ DEBT

Loan Facility

On June 9, 2022, the Company entered into the Credit Agreement with the Lender. The Credit Agreement provides for a ~~five-year~~five-year senior secured credit facility in an aggregate principal amount of up to $50 million, of which $25 million, representing the Initial Commitment Amount, was made available on the closing date and up to $25 million, representing the Delayed Draw Commitment Amount, may be made available on or prior to June 30, 2023, subject to certain revenue requirements. On June 9, 2022, the Company closed on the Initial Commitment Amount, less certain fees and expenses payable to or on behalf of the Lender.

All obligations under the Credit Agreement are guaranteed by all of the Company’s wholly owned subsidiaries other than Dario Health Services Private Limited. All obligations under the Credit Agreement, and the guarantees of those obligations, are secured by substantially all of the Company's and each guarantor's assets by a Pledge and Security Agreement, dated June 9, 2022 (the “Pledge and Security Agreement”). ~~If, until~~The Credit Agreement contains a revenue covenant effective to the maturity date, of ~~the Loan Facility,~~which if the Company’s net revenue does not equal or exceed the applicable amount for such period as set in the Credit Agreement, then the Company shall repay in equal monthly installments the outstanding principal amount of the Loan ~~Facility, together with a repayment premium and other fees.~~Facility. The Company shall repay amounts outstanding under the Loan Facility in full immediately upon an acceleration as a result of an event of default as set forth in the Credit ~~Agreement, together with a repayment premium and other fees.~~Agreement.

During the term of the Loan Facility, interest payable in cash by the Company shall accrue on any outstanding balance due under the Loan Facility at a rate per annum equal to the higher of (x) the adjusted SOFR rate (which is the forward-looking term rate for a one-month tenor based on the secured overnight financing rate administered by the CME Group Benchmark Administration Limited) and (y) 0.50% plus, in either case, 9.50%.

During an event of default, any outstanding amount under the Loan Facility will bear interest at a rate of 5.00% in excess of the otherwise applicable rate of interest.

The Credit Agreement contains customary events of default, including with respect to non-payment of principal, interest, fees or other amounts; material inaccuracy of a representation or warranty; failure to perform or observe

covenants; bankruptcy and insolvency events; material monetary judgment defaults; impairment of any material definitive loan documentation; other material adverse effects; key person events and change of control.

Each of the Credit Agreement and a Pledge and Security Agreement also contain a number of customary representations, warranties and covenants that, among other things, will limit or restrict the ability of the Company and its subsidiaries to (subject to certain qualifications and exceptions): create liens and encumbrances; incur additional indebtedness; merge, dissolve, liquidate or consolidate; make acquisitions, investments, advances or loans; dispose of or transfer assets; pay dividends or make other payments in respect of their capital stock;

amend certain material documents; redeem or repurchase certain debt; engage in certain transactions with affiliates; and enter into certain restrictive agreements. In addition, the Company will be required to maintain at least $10 million of unrestricted cash and ~~cash equivalents~~cash-equivalents at all times.

F-19

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 7: - ~~LONG TERM~~ DEBT (Cont.)

On the closing date of the Credit Agreement, and with respect to the Initial Commitment Amount only, the Company agreed to issue the Lender a warrant (the “Warrant”) to purchase up to 226,586 shares of the Company’s common stock, at an exercise price of $6.62 per share, which shall have a term of 7 years from the issuance date. The Warrant contains customary share adjustment provisions, as well as weighted average price protection in certain circumstances but in no event will the exercise price of the Warrant be adjusted to a price less than $4.00 per share. In the event the Company is eligible to draw the Delayed Draw Commitment Amount, the Company agreed to issue the Lender an additional warrant (the “Additional Warrant”), with a term of 7 years from the issuance date, to purchase up to 6% of the Delayed Draw Commitment Amount based on a ~~10 day~~10-day volume weighted average price of the Company’s common stock (the “Volume Weighted Average Price”) with an exercise price equal to the Volume Weighted Average Price.

The Company concluded that the Credit Agreement includes three legally detachable and separately exercisable freestanding financial instruments: the Initial Commitment Amount, the warrants, and the right to receive the Delayed Draw Commitment Amount, which we refer to as the "Financial Commitment Asset" or "FCA".

The Company has concluded that the warrants are not indexed to the Company's own stock and should be recorded as a liability measured at fair value with changes in fair value recognized in earnings.

The Company has also concluded that the FCA is not indexed to the Company's own stock and should be recorded as an asset, measured at fair value with changes in fair value recognized in earnings. ~~The~~During the year ended December 31, 2022, the FCA ~~is presented within other accounts receivable on the interim consolidated balance sheets.~~expired and was derecognized.

The Company elected to account for the Initial Commitment Amount under the fair value option in accordance with ASC 825, “Financial Instruments.” Under the fair value option, changes in fair value are recorded in earnings except for fair value adjustments related to instrument specific credit risk, which are recorded as other comprehensive income or loss.

During the ~~nine-month period~~three months ended ~~on September 30, 2022,~~March 31, 2023, the Company recognized ~~$200~~$291 of remeasurement ~~expenses~~incomes related to the Initial Commitment Amount, which were included as part of financial expenses ~~(income)~~ in the Company's statements comprehensive loss. During the ~~nine-month~~three-month period ended ~~on September 30,~~March 31, 2023, and the year ended December 31, 2022, the Company did not recognize any instrument specific credit risk fair value adjustment.

Pursuant to the terms of the Credit Agreement the Company started repayment of the outstanding principal amount of the Initial Commitment Amount of $25 million issued as part of the Loan Facility, together with a repayment premium and other fees in monthly installments of up to $518 beginning as of January 31, 2023, and continuing through the maturity date, or June 9, 2027.

F-20

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 8: - COMMITMENTS AND CONTINGENT LIABILITIES

From time to time, the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.

~~Royalties:~~

Royalties

The company has a liability to pay future royalties to the Israeli Innovation Authority (the “IIA”) for ~~participated~~participation in programs sponsored by the Israeli government for the support of research and development activities. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues (based on the US dollar) generated from such projects, up to 100% of the grants received. Royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales,no payment is required. During the three months ended March 31, 2023 the Company did not record IIA royalties related to the acquisition of Physimax Technology.

NOTE 9: - INTANGIBLE ASSETS


a. Definite-lived other intangible assets:
	March 31,		December 31,		Weighted
	2023		2022		Average
	Unaudited				Remaining Life
Original amounts:
Technology	$	16,936	$	16,936	2.0
Brand		376		376	1.2
		17,312		17,312
Accumulated amortization:
Technology		8,281		7,199
Brand		228		197
		8,509		7,396
Other intangible assets, net	$	8,803	$	9,916


b. Amortization expenses for the three-month period ended March 31, 2023 and for the year ended December 31, 2022 amounted to $1,113 and $4,361, respectively.

c. Estimated amortization expense:

For the year ended December 31,
Remainder of 2023	$	3,399
2024		4,452
2025		952
	$	8,803

~~F-20~~F-21

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 9:10: - STOCKHOLDERS’ EQUITY

~~On January 4, 2022, out~~In April 2020, the Compensation Committee of the ~~pre-funded warrants that were issued in May 2019, 81,233 were exercised on~~Board of Directors approved a ~~cashless basis into 81,221~~monthly grant of shares of the Company’s common ~~stock.~~Asstock equal to $18.00 of ~~September 30, 2022,~~restricted shares to certain service providers per month, to be granted monthly during the ~~Company’s~~period that the certain consulting agreement remains in effect. During the three-month period ended March 31, 2023 a total ~~outstanding prefunded warrants were exercisable into 1,769,794~~of 10,436 restricted unregistered shares of common ~~stock.~~stock, were issued to certain service providers under this approval. During the three-month period ended March 31, 2023, the Company recorded compensation expense for service providers in the amount of $43.

On February 28, 2022, the Company entered into securities purchase agreements with institutional accredited investors relating to an offering with respect to the sale of an aggregate of 4,674,454 shares of the Company’s common stock, and pre-funded warrants to purchase an aggregate of 667,559 shares of ~~the Company’s common stock~~ ~~at an exercise price of $0.0001 per share, at a purchase price of $7.49 per share (or share equivalent). The aggregate gross proceeds were approximately $40,000 ($38,023, net of issuance expenses).~~

During the ~~nine-month~~three-month period ended ~~September~~March ~~30, 2022,~~31, 2023, the Company’s Compensation Committee of the Board of Directors approved the grant of ~~29,755 shares of the Company’s common stock to employees of the Company, and the grant of 1,149,550~~105,000 restricted shares of the Company’s common stock to ~~employees~~a consultant and ~~consultants. The~~an employee. Out of the restricted shares granted, 30,000 will vest over a period of ~~three~~six months, and the remaining 75,000 restricted shares will vest over a period of two years commencing on the respective grant dates. The ~~Compensation Committee also approved the grant of options to purchase up to 813,050~~75,000 restricted shares of the Company’s common stock to employees and a consultant of the Company, at exercise prices between $5.46 and $8.10 per share. The stock options vest over a three-year period commencing on the respective grant dates. The options have a ten-year term and were issued under the Company’s 2020 Equity Incentive Plan, as amended (the “2020 Plan”).

d.c.

~~In February 2021,~~During the ~~Board of Directors authorized the Company to issue warrants to purchase up to 400,000,~~three-month period ended March 31, 2023, certain series A Convertible Preferred stockholders converted 10 shares of ~~Common Stock, to a certain consultant~~various classes of the ~~Company, at a purchase price~~Company’s A Convertible Preferred stock into 3,582 shares of ~~$25.00. During the nine-month ended~~ ~~September~~ ~~30, 2022, the Company recorded compensation expense for this certain service provider in the amount of $863.~~common stock.

In July 2021, the Compensation Committee authorized the Company to issue warrants to purchase 30,000 shares of Common Stock, to certain consultants of the Company, with an exercise price of $23.30 per share, and warrants to purchase 83,948 shares of the Company’s common stock with an exercise price of $16.06 per share. Of these warrants, warrants to purchase 35,000 shares of the Company’s common stock shall vest over a 48-month period and warrants to purchase 48,948 shares of the Company’s common stock are subjected to certain performance terms. During the nine-month ended ~~September~~ ~~30, 2022, the Company recorded compensation expense for this certain service provider in the amount of $110.~~

f.d.

In May and June 2022, the Compensation Committee authorized the Company to grant warrants to purchase up to 70,000, and 175,000 shares of the Company’s common stock which shall vest over 12 months and 24 ~~months period,~~month periods, respectively, to certain consultants of the Company, ~~at a purchase~~with an exercise price of $6.45 and $7.20, respectively. During the ~~nine-month~~three-month period ended March 31, 2023, the Company recorded a warrant compensation expense for service providers in the amount of $158.

~~September~~In December 2022, the Compensation Committee authorized the Company to issue warrants to purchase up to 500,000, shares of common stock, to a certain consultant of the Company, with an exercise price of $5.00. During the three-month period ended March 31, 2023, the Company recorded a warrant compensation expense for service provider in the amount of $175.

~~30, 2022,~~In January 2023, the Compensation Committee of the Board of Directors approved the grant of a non-qualified stock option award to purchase 100,000 shares of the Company’s common stock, as well as an additional non-qualified performance-based stock option award to purchase an additional 100,000 shares of the Company’s common stock outside of the Company’s existing equity compensation plans, pursuant to Nasdaq Listing Rule 5635(c)(4), in connection with the employment of its Senior Vice President of Growth’.

In January 2023, the Compensation Committee of the Board of Directors approved the grant of warrants to purchase up to 280,000 shares of common stock, with an exercise price of $5.20, per share to certain consultants. The warrants are exercisable into common stock on or before December 31, 2026. During the three months ended March 31, 2023, the Company recorded compensation expense for those certain service providers in the amount of ~~$215.~~$142.

g.h.

~~On June 8, 2022,~~In January 2023, the Compensation Committee ~~authorized~~approved a reduction in the ~~Company~~exercise price of fully vested stock option to ~~redeem 17,957~~purchase up to 350,000 shares of ~~restricted~~common stock ~~held by a~~issued to certain ~~officer,~~consultants in ~~compliance with Rule 16b-3 promulgated by~~ the ~~SEC, The redemption is part~~past at exercise prices between $7.50 to $30.00 per share, to an exercise price of ~~previously granted 91,652 and 20,000 shares of restricted stock granted in January and July 2021, in exchange for the aggregate redemption price equal~~$5.20 per share, subject to the ~~withholding tax obligation~~performance of additional services. The Company has accounted the change as a modification and recorded the increase in fair value as compensation expense for those certain service providers in the amount of ~~$170.~~$106.

~~F-21~~F-22

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 9:10: - STOCKHOLDERS' EQUITY (Cont.)

h.i.

~~During~~On January 30, 2023, the ~~nine-month ended~~ ~~September~~ ~~30, 2022, certain series A Convertible Preferred Stockholders converted 1,130~~Board of Directors approved to accelerate the unvested portion of 21,250 restricted shares ~~of various classes~~ of the Company’s ~~A Convertible Preferred~~common stock ~~into 277,687~~to a certain employee of the Company. The share acceleration was part of a separation agreement with the employee. The Company has accounted the acceleration as a type-3 modification and recorded compensation expenses in the amount of $97.

In February 2023, the Compensation Committee of the Board of Directors approved the grant of options to purchase up to 50,000 shares of ~~Common Stock.~~common stock, and performance-based options to purchase up to 100,000 shares of common stock to employee of the Company, at an exercise price $4.48 per share. The time vesting restricted shares and stock options vest over a period of three years commencing on the respective grant dates. The options have a ten-year term and were issued under the 2020 Plan.

On September 20, 2022, the Board of Directors authorized the Company to enter into an exchange agreement with a certain preferred stockholder to exchange 885 shares of the Company’s Series A-1 Preferred Stock for 308,711 shares of the Company’s common stock. During the nine months ended 30, 2022, the investor exchanged those certain shares. The Company has accounted for the exchange as a modification and recorded the increase in fair value as a deemed dividend in the amount of $62.

~~During the nine-month ended~~ ~~September~~ ~~30, 2022, 61,730 shares of the Company’s common stock were issued as dividend to certain Series A Convertible Preferred stockholders upon conversion of such shares.~~

i.k.

Stock ~~based compensation:~~plans:

On January 23, 2012, the Company’s Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) was adopted by the Board of Directors of the Company and approved by a majority of the Company’s stockholders, under which options to purchase shares of the Company’s common stock have been reserved. Under the 2012 Plan, options to purchase shares of ~~Common Stock may be granted to employees and non-employees of the Company or any affiliate, each option granted can be exercised to one share of Common Stock. The 2012 Plan has expired.~~

On October 14, 2020, the Company’s stockholders approved the 2020 Plan and the immediate reservation of 900,000 shares under the 2020 Plan for the remainder of the 2020 fiscal year. Under the 2020 Plan, options to purchase shares of the Company’s common stock may be granted to employees and non-employees of the Company or any affiliate, each option granted can be exercised to one share of ~~Common Stock.~~common stock. The 2012 Plan has expired.

In January ~~2022,~~2023, pursuant to the terms of the 2020 Plan as approved by the Company’s stockholders, the Company increased the number of shares authorized for issuance under the 2020 Plan by ~~1,339,624~~1,994,346 shares, from ~~2,528,890~~3,868,514 to ~~3,868,514.~~5,862,860.

~~On April 23, 2022,~~Transactions related to the ~~Company released 56,788 holdback shares~~grant of options to employees, directors and non-employees under the ~~Company’s common stock to certain employee of~~above plans and non-plan options during the ~~Company. The holdback release was part of a separation agreement with the employee, pursuant to which the Company waived the lock-up period.~~three-months period ended March 31, 2023, (unaudited) were as follows:


			Weighted
		Weighted	average
		average	remaining	Aggregate
		exercise	contractual	Intrinsic
	Number of	price	life	value
	options	$	Years	$
Options outstanding at beginning of period	2,124,302	13.38	6.98	121
Options granted	350,000	5.33	—	—
Options expired	(121,352)	27.23	—	—
Options forfeited	(109,673)	7.41	—	—

Options outstanding at end of period	2,243,277	11.66	7.23	116

Options vested and expected to vest at end of period	1,857,200	12.09	7.11	115

Exercisable at end of period	1,080,195	15.47	5.33	116

~~F-22~~F-23

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 9:10: - STOCKHOLDERS' EQUITY (Cont.)

~~Transactions related to the grant of options to employees, directors, and non-employees under the above plans during the nine-months period ended~~ ~~September~~ ~~30, 2022, were as follows:~~

Weighted


Weighted

average

average

remaining

Aggregate

exercise

contractual

Intrinsic

Number of

price

life

value

options

$

Years

$
Options outstanding at beginning of period

1,878,168

18.13

6.96

3,861
Options granted

813,050

7.02

—

—
Options exercised

—

—

—
Options expired

(115,271)

17.74

—

—
Options forfeited

(409,410)

14.95

—

—

Options outstanding at end of period

2,166,537

14.59

7.07

131

Options vested and expected to vest at end of period

2,021,479

14.71

7.03

131

Exercisable at end of period

978,807

18.72

5.55

131

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price on the last day of the first quarter of ~~2022~~2023 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on ~~September~~March ~~30, 2022.~~31, 2023. This amount is impacted by the changes in the fair market value of the ~~Common Stock.~~

common stock.

Transactions related to the grant of restricted shares to employees, directors, and non-employees under the above plans during the ~~nine-months~~three-month period ended ~~September 30, 2022,~~March 31, 2023, (unaudited) were as follows:


								Number of
								Restricted shares

Restricted shares outstanding at beginning of period								~~1,094,627~~2,207,772
Restricted shares granted								~~1,149,550~~110,000
Restricted shares forfeited								~~(103,381)~~(3,193)

Restricted shares outstanding at end of period								~~2,140,796~~2,314,579

As of ~~September 30, 2022,~~March 31, 2023, the total amount of unrecognized stock-based compensation expense was approximately ~~$26,245~~$18,601 which will be recognized over a weighted average period of ~~1.19~~1.01 years.

~~F-23~~

~~Table of Contents~~

~~DARIOHEALTH CORP. AND ITS SUBSIDIARIES~~

~~NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS~~

~~U.S. dollars in thousands (except stock and stock data)~~

~~NOTE 9: - STOCKHOLDERS' EQUITY (Cont.)~~

The following table presents the assumptions used to estimate the fair values of the options granted to employees, directors, and non-employees in the period presented:

Three months ended

September 30,


2022

2021



Volatility

92.25
-
92.60
%
93.34
-
96.01
%

Risk-free interest rate

2.70
-
3.01
%
0.01
-
0.01
%

Dividend yield

-

-
%
-

-
%

Expected life (years)

5.81
-
5.88

5.25
-
5.88

~~The total compensation cost related to all of the Company’s stock-based awards recognized during the nine-month period ended September 30, 2022, and 2021 was comprised as follows:~~

Nine months ended

September 30,

2022

2021

Unaudited

Cost of revenues

$
72

$
63

Research and development

3,215

2,480

Sales and marketing

5,089

4,007

General and administrative

5,522

12,120

Total stock-based compensation expenses

$
13,898

$
18,670

~~NOTE 10: - FINANCIAL EXPENSES (INCOME), NET~~

Nine months ended

September 30,

2022

2021

Unaudited

Bank charges

$
59

$
60

Foreign currency adjustments expenses, net

51

322

Interest income

(228)

(36)

Loan Interest Expenses

969

—

Remeasurement of long-term loan

976

—

Remeasurement of warrant liability

(929)

—

Debt issuance cost

724

—

Remeasurement of FCA

153

—

Total Financial expenses (income), net

$
1,775

$
346


	Three months ended
	March 31,
	2023		2022

	Unaudited
Volatility	92.05-92.62	%	91.11-91.40	%
Risk-free interest rate	3.54-4.13	%	1.89	%
Dividend yield	0	%	0	%
Expected life (years)	5.81-5.88		5.81-5.88

F-24

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 10: - STOCKHOLDERS' EQUITY (Cont.)

The total compensation cost related to all of the Company’s stock-based awards recognized during the three-month period ended March 31, 2023, and 2022 was comprised as follows:


	Three months ended
	March 31,
	2023		2022

	Unaudited
Cost of revenues	$	27	$	23
Research and development		1,185		1,488
Sales and marketing		1,847		1,651
General and administrative		1,797		2,181

Total stock-based compensation expenses	$	4,856	$	5,343

NOTE 11: - SELECTED STATEMENTS OF OPERATIONS DATA


	Three months ended
	March 31,
	2023		2022

	Unaudited
Bank charges	$	49	$	26
Foreign currency adjustments expenses, net		(62)		22
Interest income		(335)		(4)
Revaluation of marketable securities		(16)		—
Loan Interest Expenses		1,072		—
Remeasurement of long-term loan		(211)		—
Remeasurement of warrant liability		(80)		—

Total Financial expenses, net	$	417	$	44

F-25

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE ~~11:~~12: - BASIC AND DILUTED NETLOSSPER COMMON STOCK

We compute net loss per share of common stock using the two-class method. Basic net loss per share is computed using the weighted-average number of shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares and the effect of potentially dilutive securities outstanding during the period.

The total number of potential shares of common stock related to the outstanding options, warrant and preferred shares excluded from the calculations of diluted net loss per share due to their anti-dilutive effect was ~~6,804,530~~5,655,446 and ~~5,987,711~~6,743,093 for the ~~nine~~three months ended ~~September 30,~~March 31, 2023, and 2022, ~~and 2021,~~ respectively.

The following table sets forth the computation of the Company’s basic and diluted net loss per common stock:


	Nine months ended				Three months ended
	September 30,				March 31,
	2022		2021		2023		2022

	Unaudited				Unaudited
Net loss attributable to common stock shareholders used in computing basic net loss per share	$	46,336	$	48,357	$	12,429	$	14,509

Weighted average number of common stock used in computing basic loss per share		22,876,397		16,202,541		27,570,013		19,624,079

Basic net loss per common stock	$	2.03	$	2.98	$	0.45	$	0.74

F-26

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE ~~12:~~13: - SUBSEQUENT EVENTS

In April 2023, the Company issued 76,637 shares of common stock to settle an earn-out in connection with the acquisition of wayForward.

On May 1, 2023, the Company entered into securities purchase agreements with accredited investors relating to an offering and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the “Series B Preferred Stock”), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the “Series B-1 Preferred Stock”), and an aggregate of 150 shares of Series B-2 Preferred Stock (the “Series B-2 Preferred Stock”) at a purchase price of $1,000 for each share of Preferred Stock. Certain of our executive officers and directors purchased shares of Series B-2 Preferred Stock in the Offering. On May 5, 2023, the Company entered into purchase agreements with accredited investors, relating to the offering of 1,106 shares of newly designated Series B-3 Preferred Stock (the “Series B-3 Preferred Stock” and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the “Preferred Stock”), at a purchase price of $1,000 for each share of Preferred Stock. As a result of the sale of the Preferred Stock, the aggregate gross proceeds to the Company from the Offering are approximately $15,400. In addition, the Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. The holders of Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of common stock equal to five percent (5.0%) of the number of shares of common stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Preferred Stock then held by such holder on the fifth full quarter from the Closing Date.

On May 1, 2023, the Company entered into agreements with certain holders of 3,557 of the Company’s Series A-1 Preferred stock pursuant to a subscription agreement dated November 27, 2019, which are convertible to 1,273,499 shares of common stock. In consideration for deferring the conversion of the Series A-1 Convertible Preferred Stock, the Company agreed to issue additional shares of common stock upon the deferred conversion of the Series A-1 Convertible Preferred Stock as follows: 63,675 shares, in the aggregate, if not converted for at least one quarter, 127,350 shares, in the aggregate, if not converted for at least two quarters, 191,026 shares, in the aggregate, if not converted for at least three quarters, 254,700 shares if not converted for at least four quarters and 382,050 shares, in the aggregate, if not converted for at least five quarters.

On May 1, 2023, the Company refinanced its existing $25,000 credit facility with a new $30,000 credit facility a Loan and Security Agreement, and Supplement thereto (the “LSA”), by and between the Company and its subsidiary, PsyInnovations Inc. collectively as the borrowers (the “Borrowers”) and Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., collectively as the lenders (the “Lenders”). The LSA provides for a four-year secured credit facility in an aggregate principal amount of up to $40,000 (the “Loan Facility”), of which $30,000 was made available on the closing date (the “Initial Tranche”) and up to $10,000 (the “Discretionary Tranche”) may be made available on the later of July 1, 2023 or the date the Lender approves the issuance of the Discretionary Tranche. On May 1, 2023, the Borrowers closed on the Initial Tranche, less certain fees and expenses payable to or on behalf of the Lenders.

~~In October~~During the term of the Loan Facility, interest payable in cash by the Borrowers shall accrue on any outstanding balance due under the Loan Facility at a rate per annum equal to the higher of (x) the sum of four one-half percent (4.50%) plus the prime rate as published in the Wall Street Journal and ~~November 2022,~~(y) twelve and one-half percent (12.50%). During an event of default, any outstanding amount under the Loan Facility will bear interest at a rate of 5.00% in excess of the otherwise applicable rate of interest. The Borrowers will pay certain fees with respect to the Loan Facility, including an upfront commitment fee, an administration fee and a prepayment premium, as well as certain other fees and expenses of the Lenders.

F-27

Table of Contents

DARIOHEALTH CORP. AND ITS SUBSIDIARIES

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands (except stock and stock data)

NOTE 13: - SUBSEQUENT EVENTS (Cont.)

On the closing date, and with respect to the Initial Tranche only, the Company ~~issued~~agreed to issue for each Lender a ~~total of 7,705 restricted~~warrant (the “Warrant”) to purchase up to 292,442 shares of the Company’s common stock, at an exercise price of $3.334 per share, which shall have a term of five years from the issuance date. The Warrant contains customary share adjustment provisions, as well as adjustments to the number of shares issuable upon exercise of the Warrant and the exercise price in the event of a ~~certain service provider, with such issuances approved by~~bona fide equity raise prior to September 30, 2023 at a price less than the then current exercise price.

The Lenders have the right, at any time while the Loan Facility is outstanding, to convert an amount of up to $2,000 of the principal amount of the outstanding Loan Facility into Borrower’s unrestricted shares of the Company’s ~~Compensation Committee~~common stock at a price per share equal to 120% of the ~~Board~~then effective exercise price of ~~Directors.~~the Warrant.

On April 13, 2023, the Company’s Compensation Committee of the Board of Directors approved the grant of 415,600 restricted shares of the Company’s common stock to employees under the 2020 Plan. The shares vest over a period of three years commencing on the respective grant dates. The Compensation Committee also approved the grant of options to purchase up to 627,100 shares of common stock to employees and a consultant of the Company, at exercise prices between $3.92 and $4.174 per share. The stock options vest over a three-year period commencing on the respective grant dates. The options have a ten-year term and were issued under the 2020 Plan.

~~F-25~~F-28

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our Annual Report for the fiscal year ended December 31, ~~2021~~2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

The following financial data in this narrative are expressed in thousands, except for stock and stock data or as otherwise noted.

We are revolutionizing how people with chronic conditions manage their health through the innovation of a new category of digital health: Digital Therapeutics as a Service ~~(DTaaS)~~(“DTaaS”). We believe that our innovative approach to digital therapeutics disrupts the traditional provider-centered system of ~~health care~~healthcare delivery by offering user-centric care that is continuous, customized ~~and multi-condition.~~supportive of better overall health. Our solutions combine the power of technologies and behavior science to make better health accessible, affordable, and easy for all by solving for what people need, when and where they want it, with hyper-personalized care that is always connected – to services, devices, and people – and delivered continuously. ~~This is how we deliver meaningful~~Our solutions are proven to drive savings for health plans and ~~sustainable results that result in measurable value for all stakeholders, supporting~~employers by improving the ~~full transformation~~health of ~~health care into a more effective and affordable ecosystem.~~their populations.

We began as a direct-to-consumer digital therapeutics company, solving first for the problem of how to engage users and support behavior change to improve clinical outcomes in diabetes. ~~In the last two years, we made two~~Beginning in 2020, Dario enacted a strategic ~~shifts~~shift to transform the business model by deploying a business-to-business-to-consumer (“B2B2C”) approach, leveraging the strengths of our ~~business: first, we significantly expanded~~consumer solution platform to enable commercial growth opportunities ~~by adding a business-to-business product (B2B) and a commercial team alongside the legacy direct-to-consumer channel. In addition, we began targeting three~~in traditional health business ~~verticals –~~channels by selling to health plans ~~employers,~~ and ~~provider groups. As a result, we believe that our new B2B business now leverages our consumer-centric capabilities as a competitive advantage.~~employers

~~Second,~~At the same time, we ~~transitioned~~expanded from a ~~single condition~~single-condition platform to a multi-condition platform, creating a robust suite of solutions to address the five most commonly co-occurring, behaviorally driven, and expensive chronic conditions, which are also representative of some of the most sought-after digital health solutions: diabetes, hypertension, pre-diabetes/weight management, musculoskeletal and behavioral health. After building weight loss and hypertension management into the legacy diabetes platform, we made three acquisitions in order to expand into musculoskeletal (“MSK”) and behavioral ~~health.~~

~~Our acquisition of~~health (“BH”). In that regard, we acquired Upright Technologies Ltd. (“Upright”) ~~in early 2021~~, PsyInnovations Inc. (“PsyInnovations”) and Physimax Technology assets to expand into the fields of MSK and BH . Our approach to integrating all solutions into one digital therapeutics platform follows the “best-of-suite” offering design principal which provides the user one place to monitor all identified chronic conditions and to deliver a seamless user experience for commonly co-occurring chronic conditions.

These two shifts led to the rapid expansion of our B2B2C business over the last two years and positioned the company for success in ~~early~~commercial markets. We continue to achieve key benchmarks as we rapidly scale our B2B2C model, including more than 100 total signed contracts as of today and the shift in our commercial pipeline where more than 50% of the contracts signed in the second half of 2022 ~~enables~~are for multi-chronic solutions. We believe we have a unique and defensible position in the market thanks to our ~~musculoskeletal (“MSK”) solutions – “Dario Move.”, our digital behavioral health capabilities were secured through the acquisition~~unique solution origin in consumer markets.

We continue to generate a significant number of ~~PsyInnovations, Inc. (dba WayForward)~~clinical publications. In that regard, we have published 40 real world data studies with total of 10 and 3 generated in ~~mid-2021.~~2022 and 2023, respectively, and several more already planned for 2023.

We believe ~~a key success factor is~~that we are proving the value of our ability to integrate multiple chronic conditions into a single digital therapeutics’ platform, the “Dario One.” During 2021 we successfully won contracts in all three B2B business segments, including several contracts for Dario One, creating a compounding effectsolutions as ~~more members enroll and many in multiple programs. The combination of moving from direct-to-consumer to the~~ enterprise business ~~market (B2B2C) and expanding from a single condition~~sales continue to ~~multi condition platform, created multiple commercial growth engines as well as a multiplying impact~~grow. With more than 100 signed contracts to date, we have solid evidence on the key differentiators that ~~we believe will improve our financial profile by increasing potential revenue per account and per user.~~

~~According~~lead to our management’s estimates, based on our current cash on hand and further based on our budget and the assumption that initial commercial sales will commence during our anticipated timeframes, we believe that we will have sufficient resources to continue our activities through 2023.

Since we might be unable to generate sufficient revenue or cash flow to fund our operations for the foreseeable future, we will need to seek additional equity or debt financing to provide the capital required to maintain or expand ournew business

Table of Contents

~~operations. We may also need additional funding for developing products~~opportunities: a consumer-friendly approach that drives engagement; deep integration capabilities; and services, increasing our sales and marketing capabilities, and promoting brand identity, as well as for working capital requirements and other operating and general corporate purposes. Moreover, the regulatory compliance arising out of being a publicly registered company has dramatically increased our costs.

Except as otherwise disclosed herein, we currently do not have any arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay, scale back or eliminate the development of business opportunities and our operations and financial condition may be materially adversely affected.

If we raise additional capital by issuing equity securities, the percentage ownership of our existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. Given our need for cash and that equity raising is the most common type of fundraising for companies like ours, the risk of dilution is particularly significant for stockholders of our company.

Debt financing, if obtained, may involve agreements that include liens on our assets, covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, could increase our expenses and require that our assets be provided as a security for such debt. Debt financing would also be required to be repaid regardless of our operating results.

If we raise additional funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate products, or to grant licenses on terms that are not favorable to us.

Funding from any source may be unavailable to us on acceptable terms, or at all. If we do not have sufficient capital to fund our operations and expenses, we may not be able to achieve or maintain competitiveness, which could lead to the failure of our business and the loss of your investment.best-in-class clinical outcomes.

Recent Developments

~~Employer Contracts~~PIPE Financing

On May 1, 2023, we entered into securities purchase agreements (each, a “Series B Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the “Series B Preferred Stock”), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the “Series B-1 Preferred Stock”), and an aggregate of 150 shares of Series B-2 Preferred Stock (the “Series B-2 Preferred Stock”) at a purchase price of $1,000 for each share of Preferred Stock. Certain of our executive officers and directors purchased shares of Series B-2 Preferred Stock in the Offering. On May 5, 2023, we entered into purchase agreements (the “Series B-3 Purchase Agreement” and together with the Series B Purchase Agreement, the “Purchase Agreement”) with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the “Series B-3 Preferred Stock” and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the “Preferred Stock”), at a purchase price of $1,000 for each share of Preferred Stock. As a result of the sale of the Preferred Stock, the aggregate gross proceeds to us from the Offering are approximately $15.4 million.

On May 1, 2023, we filed the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, the Certificate of Designation of Preferences, Rights and Limitations of the Series B-1 Preferred Stock, and the Certificate of Designation of Preferences, Rights and Limitations of the Series B-2 Preferred Stock with the Secretary of State of the State of Delaware (the “Series B Certificate of Designation,” the “Series B-1 Certificate of Designation,” and the “Series B-2 Certificate of Designation”). On May 5, 2023, the Company filed the Certificate of Designation of Preferences, Rights and Limitations of the Series B-3 Preferred Stock (the “Series B-3 Certificate of Designation,” and together with the “Series B Certificate of Designation,” the “Series B-1 Certificate of Designation,” and the “Series B-2 Certificate of Designation, collectively, the “Certificates of Designation”). Each share of Preferred Stock is convertible at the option of the holder, subject to certain beneficial ownership limitations as set forth in each of the Certificates of Designation, into such number of shares of our equal to the number of Preferred Shares to be converted, multiplied by the stated value of $1,000 (the “Stated Value”), divided by the conversion price in effect at the time of the conversion (the initial conversion price of the Series B Preferred Stock and Series B-1 Preferred Stock is $3.334, the initial conversion price of the Series B-2 Preferred Stock is $3.37, and the initial conversion price of the Series B-3 Preferred Stock is $3.392) each subject to adjustment in the event of stock splits, stock dividends, and similar transactions.

In ~~September 2022,~~addition, the Preferred Stock will automatically convert into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date. The holders of Preferred Stock will also be entitled dividends payable as follows: (i) a number of shares of common stock equal to five percent (5.0%) of the number of shares of common stock issuable upon conversion of the Preferred Stock then held by such holder for each full quarter anniversary of holding for a total of four (4) quarters from the Closing Date, and (ii) a number of shares of common stock equal to ten percent (10%) of the number of shares of common stock issuable upon conversion of the Preferred Stock then held by such holder on the fifth full quarter from the closing date.

Loan Facility

On May 1, 2023, we ~~announced two new employer contracts, including one for the full suite of integrated solutions, which are scheduled to launch in late 2022~~entered into a Loan and ~~early 2023.~~

In October 2022, we announced that a mid-sized Midwestern city selected us to provide our full suite of digital therapeutics solutions to several thousand city employees beginning in the first quarter of 2023.

~~In October 2022, we announced that our full suite of chronic condition management solutions was selected~~Security Agreement, and Supplement thereto (the “LSA”), by ~~two employers to help improve overall employee health beginning in the first quarter of 2023.~~

~~Presentation of New Studies~~

~~In September 2022, we announced new research examining the link~~and between the ~~use~~us and our subsidiary, PsyInnovations Inc. (“PsyInnovations”), collectively as the borrowers (the “Borrowers”) and Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P., collectively as the lenders (the “Lenders”). The LSA provides for a four-year secured credit facility in an aggregate principal amount of ~~our biofeedback device~~up to ~~help users improve their posture~~$40 million (the “Loan Facility”), of which $30 million was made available on the closing date (the “Initial Tranche”) and ~~reduced back pain, which was presented at~~up to $10 million (the “Discretionary Tranche”) may be made available on the ~~International Association~~later of July 1, 2023 or the date the Lender approves the issuance of the ~~Study of Pain (IASP) 2022 World Congress~~Discretionary Tranche. On May 1, 2023, the Borrowers closed on ~~Pain. The research examined~~ the ~~connection between users of our posture trainer, posture awareness~~Initial Tranche, less certain fees and ~~the impact~~expenses payable to or on ~~levels of pain. Our posture training solution, part~~behalf of the Dario Move suite of musculoskeletal solutions, helps users develop better posture through the use of a wearable biofeedback sensor that vibrates when the user is in a slouching position. Over the course of time, this trains users, helping them to develop awareness and adoption of proper posture. We analyzed the data from close to 1,000 individuals who reported high levels of pain in their initial assessment and who conducted six or more hours a week of posture training for at least eight weeks. This data set allowed researchers to demonstrate that increased time wearing the posture trainer was predictive of posture quality which, in turn, was predictive of the level of pain, establishing the linkage between postural digital biofeedback technology and back pain reduction.Lenders.

Table of Contents

As a result of the execution of the LSA and the funding of the Initial Tranche, the Company satisfied its prior Credit Agreement it previously executed with OrbiMed Royalty and Credit Opportunities III, LP (“Orbimed”), on June 9, 2022 and terminated the Credit Agreement with Orbimed.

Employer Contracts

In March 2023, we announced a new contract with a leading nationwide pharmacy benefits manager, operating in 50 states to provide our digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023.

In March 2023, we announced a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Our solution will be available through Amwell beginning in the second half of 2023.

New Hires

In April 2023, we announced the hiring of Mr. Eitan Shay as our Chief Product Officer and Mr. Arnaud Robert, as a Strategic Advisor to our Chief Executive Officer.

Presentation of New Studies

In March 2023, we announced new research investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models. We set out to determine the effectiveness of deploying adapted machine learning to analyze and personalize user journeys in its posture training solution. We analyzed data from 3,610 users who experienced significant reductions in back pain reported after three weeks using the Company's posture training program with sustained improvement. Users' profile moderated time fluctuations of pain levels and posture quality over time. The data was then analyzed to investigate how the use of machine learning can account for unique individual needs. The results of the study offer a framework to help understand the efficacy of digital therapeutics in helping individuals manage pain.

In May 2023, we announced the results of a study completed by Sanofi which demonstrated significant reductions in healthcare resource utilization for Dario users compared to non-users. The study conducted by Sanofi and presented at the ISPOR conference, demonstrated a statistically significant 9.3% reduction in all-cause Heath Care Resource Utilization (HCRU), including a 23.5% reduction in hospitalizations, in Dario users after 12 months. This impact of our digital diabetes solution across total health care utilization provides evidence that a whole-health approach to managing chronic conditions like diabetes can potentially reduce utilization rates that lead to potential cost savings.

Results of Operations

Comparison of the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023, and March 31, 2022 ~~and 2021~~ (dollar amounts in thousands)

Revenues

Revenues for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, amounted to ~~$6,605~~ ~~and $~~20~~,847 respectively,~~$7,066, compared to revenues of ~~$5,629 and $14,485~~$8,059 during the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, representing ~~an increase~~a decrease of ~~17% and 44%, respectively.~~12.3%. The ~~increase~~decrease in revenues for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, compared to the three ~~and nine~~ months ended ~~September 30, 2021, is due to an increase~~ inMarch 31, 2022, resulted mainly from lower revenues from ~~sales through our B2B channel~~.the Company’s consumer (B2C) channel.

Cost of Revenues

During the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, we recorded ~~cost of~~costs related to revenues in the amount of ~~$4,805 and $1~~3,~~924, respectively,~~$3,898, compared to costs ofrelated to revenues of $~~4,803 and $11,070~~ $4,074 during the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, representing a ~~zero and 25.8% increase, respectively.~~decrease of 4.3%. The ~~increase~~decrease in cost of revenues in the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, compared to the ~~nine~~three months ended ~~September 30, 2021, resulted from including payroll development costs in the~~March 31, 2022, was mainly due to lower cost of revenues ~~which were incurred during~~from the ~~period~~.Company’s consumer channel.

Table of Contents

Cost of revenues consist mainly of cost of device production, employees’ salaries and related overhead costs, depreciation of production line and related cost of equipment used in production, amortization of technologies, hosting costs, shipping and handling costs and inventory write-downs.

Gross Profit

Gross profit for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, amounted to $1~~,800 (27.3%~~$3,168 (44.8% of revenues) ~~and $6,923 (33.2% of revenues), respectively~~ compared to ~~$826 (14.7% of revenues) and $3,415 (23.6%~~$3,985 (49.4% of revenues) during the three ~~and nine~~ months ended ~~September 30, 2021.~~March 31, 2022. The ~~increase~~decrease in gross profit as a percentage of revenue for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, compared to the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, is due to ~~the~~higher cost of revenues ~~derived from sales through our B2B channel. Gross profit for~~related to services in the three ~~and nine~~ months ended ~~September 30, 2022, excluding amortization of acquired technology and inventory step-up were $2,905 (44% of revenues) and $10,054 (48.2% of revenues)~~March 31, 2023, compared to ~~$2,532 (45% of revenues) and $6,739 (46.5% of revenues) during~~ the three ~~and nine months~~Months ended ~~September 30, 2021.~~March 31, 2022.

Research and Development Expenses

Our research and development expenses decreased by ~~$703,~~$762, or ~~12.8%~~12.9%, to ~~$4,803~~$5,165 for the three months ended ~~September 30, 2022,~~March 31, 2023, compared to ~~$5,506~~$5,927 for the three months ended ~~September 30, 2021, and increased by $2,964, or 24.9%, to $14,867 for the nine months ended September 30, 2022, compared to $11,903 for the nine months ended September 30, 2021. The~~March 31, 2022. This decrease ~~for the three months ended September 30, 2022~~ was mainly a result of ~~a decrease in~~lower payroll, ~~expenses. The increase for~~ the ~~nine months ended September 30, 2022 was mainly a result~~use of ~~expanding our research~~fewer subcontractors, and ~~development activities.~~reduced stock-based compensation expenses. Our research and development expenses, excluding stock-based compensation and depreciation, for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, were ~~$3,625 and $11,620~~$3,961 compared to ~~$3,854 and $9,155~~$4,428 for the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, a decrease of ~~$229 and increase of $2,465, respectively.~~$467.

Research and development expenses consist mainly of ~~payroll expenses to employees~~employees’ salaries and related overhead costs involved in research and development activities, expenses related to: (i) our solutions including our Dario Smart Diabetes Management Solution, DarioEngage platform, Dario Move solution and our digital behavioral health solution, (ii) labor contractors and engineering expenses, (iii) depreciation and maintenance fees related to equipment and software tools used in research and development, (iv) clinical trials performed in the United States to satisfy the FDA product approval requirements and (v) facilities expenses associated with and allocated to research and development activities. We view research and development as a principal strategic investment and have continued our commitment to invest in this area. We will need to continue to invest in research and development and such expenses may increase in the future to keep pace with new trends in our industry.

~~Table of Contents~~

Sales and Marketing Expenses

Our sales and marketing expenses decreased by ~~$3,125,~~$3,195, or ~~29.2%,~~33.5 %, to ~~$7,571~~$6,340 for the three months ended ~~September 30, 2022,~~March 31, 2023, compared to ~~$10,696~~$9,535 for the three months ended ~~September 30, 2021, and decreased by $1,073, or 3.9%, to $26,403 for the nine months ended September 30, 2022, compared to $27,476 for the nine months ended September 30, 2021.~~March 31, 2022. The decrease was mainly due ~~a decrease~~to decreases in our digital marketing expenses, ~~partially offset by an increase in stock-based compensation~~payroll and ~~payroll~~ related expenses. Our sales and marketing expenses, excluding stock-based compensation and depreciation, for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023, were ~~$5,570 and $20,96~~$4,449 compared to ~~$8,780 and $23,322~~$7,843 for the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, a decrease of ~~$3,210 and $2,356, respectively.~~$3,394.

Sales and marketing expenses consist mainly of ~~payroll expenses,~~employees’ salaries and related overhead costs, online marketing campaigns of our service offering, ~~and other costs associated with sales and marketing activities, as well as~~ trade show expenses, customer support expenses and marketing consultants, marketing expenses and subcontractors.

General and Administrative Expenses

Our general and administrative expenses decreased by ~~$3,124,~~$324, or ~~43.8%~~7.4%, to ~~$3,999~~$4,071 for the three months ended ~~September 30, 2022,~~March 31, 2023, compared to ~~$7,123~~$4,395 for the three months ended ~~September 30, 2021, and decreased by $5,412, or 28.7% to $13,453 for the nine months ended September 30, 2022, compared to $18,865 for the nine months ended September 30, 2021.~~March 31, 2022. This decrease was mainly due to ~~decreases~~a decrease in stock-based compensation expenses during the three ~~and nine~~ months ended ~~September 30, 2022.~~March 31, 2023. Our general and administrative expenses, excluding stock-based compensation, depreciation ~~acquisition related costs~~ and earn-out remeasurement for the three ~~and nine~~ months ended ~~September 30, 2022~~March 31, 2023, were ~~$2,170 and $7,099,~~$2,239 compared to ~~$1,873 and $6,124~~$2,552 for the three ~~and nine~~ months ended ~~September 30, 2021, an increase~~March 31, 2022, a decrease of ~~$297 and $975, respectively.~~$313.

Our general and administrative expenses consist mainly of ~~payroll~~employees’ salaries and ~~stock-based compensation expenses for management, employees,~~related overhead costs, directors fees, legal and ~~consultants, legal~~accounting fees, ~~directors’ and officers’ insurance,~~ patent registration, expenses related to investor relations, as well as our office rent and related expenses.

Financial ~~(Income)~~ Expenses, net

Our financial expenses, net for the three months ended ~~September 30, 2022,~~March 31, 2023, were ~~$1,059,~~$417, representing an increase of ~~$1,114,~~$373, compared to financial ~~income~~expenses of ~~$55~~$44 for the three months ended September 30, 2021. Our financial expenses, net for the nine months ended September 30, 2022, were $1,775, representing increase of $1,429, compared to financial expenses of $346 for the nine months ended September 30, 2021.March 31, 2022. The increase in our financial expenses was mainly due to ~~cost related to obtaining the credit facility agreement dated June 9, 2022 and~~ interest expense ~~for the period from June 9, 2022~~on our long-term loan in the amount of ~~$1,693~~$1,072 partially offset by interest income and ~~due to~~the revaluation of short-term investments in the amount of $351 and the revaluation of the long-term loan and the warrant liability, ~~and the financial commitment asset relating to our loan from OrbiMed Royalty and Credit Opportunities III, LP, as the lender (the “Lender”),~~ in the amount of ~~$200.~~$291.

Table of Contents

Financial expenses, net primarily consists of credit facility interest expense, ~~debt issuance costs,~~ interest income from cash balances, the revaluation of short-term investments, bank charges, lease liability and foreign currency translation differences.

Net loss

Net loss decreased by ~~$6,812,~~$3,091, or ~~30.4%~~19.4%, to ~~$15,632~~$12,825 for the three months ended ~~September 30, 2022,~~March 31, 2023, compared to a net loss of ~~$22,444~~$15,916 for the three months ended ~~September 30, 2021, and decreased by $5,599, or 10.1%, to $49,576 for the nine months ended September 30, 2022, compared to a net loss of $55,175 for the nine months ended September 30, 2021.~~March 31, 2022. The decrease in net loss for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, compared to the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, was mainly due to ~~the increase in our gross profit and~~ the decrease in our operating expenses.

The factors described above resulted in net loss attributable to common stockholders for the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, amounted to ~~$16,126 and $50,954, respectively,~~$12,825, compared to net loss attributable to common stockholders of ~~$22,932 and $56,695.~~$16,367 for the three months ended March 31, 2022.

~~Table of Contents~~

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) within this Quarterly Report on Form 10-Q, management provides certain non-GAAP financial measures (“NGFM”) of the Company’s financial results, including such amounts captioned: “net loss before interest, taxes, depreciation, and amortization” or “EBITDA”, and “Non-GAAP Adjusted Loss”, as presented herein below. Importantly, we note the NGFM measures captioned “EBITDA” and “Non-GAAP Adjusted Loss” are not recognized terms under U.S. GAAP, and as such, they are not a substitute for, considered superior to, considered separately from, nor as an alternative to, U.S. GAAP and /or the most directly comparable U.S. GAAP financial measures.

Such NGFM are presented with the intent of providing greater transparency of information used by us in our financial performance analysis and operational decision-making. Additionally, we believe these NGFM provide meaningful information to assist investors, shareholders, and other readers of our unaudited condensed consolidated financial statements, in making comparisons to our historical financial results, and analyzing the underlying financial results of our operations. The NGFM are provided to enhance readers’ overall understanding of our current financial results and to provide further information to enhance the comparability of results between the current year period and the prior year period.

We believe the NGFM provide useful information by isolating certain expenses, gains, and losses, which are not necessarily indicative of our operating financial results and business outlook. In this regard, the presentation of the NGFM herein below, is to help the reader of our unaudited condensed consolidated financial statements to understand the effects of the non-cash impact on our (U.S. GAAP) unaudited condensed consolidated statement of operations of the revaluation of the warrants and the expense related to stock-based compensation, each as discussed herein above.

Table of Contents

A reconciliation to the most directly comparable U.S. GAAP measure to NGFM, as discussed above, is as follows:


	Three Months Ended September 30,						Three Months Ended March 31,
	(in thousands)						(in thousands)
	2022		2021		$ Change		2023		2022		$ Change
Net Loss Reconciliation
Net loss - as reported	$	(15,632)	$	(22,444)	$	6,812	$	(12,825)	$	(15,916)	$	3,091

Adjustments
Depreciation expense		89		69		20		97		70		27
Inventory step up amortization		—		462		(462)
Amortization of acquired technology and brand		1,136		1,290		(154)		1,113		963		150
Other financial expenses (income), net		1,059		(55)		1,114
Other financial expenses, net								417		44		373

EBITDA		(13,348)		(20,678)		7,330		(11,198)		(14,839)		3,641

Acquisition costs								—		87		(87)
Earn-out remeasurement		6		—		6		—		(452)		452
Stock-based compensation expenses		4,926		8,770		(3,844)		4,856		5,343		(487)

Non-GAAP adjusted loss	$	(8,416)	$	(11,908)	$	3,492	$	(6,342)	$	(9,861)	$	3,519

~~Table of Contents~~

Nine Months Ended September 30,

(in thousands)

2022

2021

$ Change
Net Loss Reconciliation






Net loss - as reported

$
(49,576)

$
(55,175)

$
5,599

Adjustments






Depreciation expense

243

202

41
Inventory step up amortization

—

985

(985)
Amortization of acquired technology and brand

3,224

2,396

828
Other financial expenses, net

1,775

346

1,429
Income Tax

1

—

1

EBITDA

(44,333)

(51,246)

6,913

Acquisition costs

—

880

(880)
Earn-out remeasurement

945

—

945
Stock-based compensation expenses

13,898

18,670

(4,772)

Non-GAAP adjusted loss

$
(29,490)

$
(31,696)

$
2,206

Liquidity and Capital Resources (amounts in thousands except for share and share amounts)

As of ~~September 30, 2022,~~March 31, 2023, we had approximately ~~$57,081~~$43,093 in cash and cash equivalents and short-term investments compared to ~~$35,808~~$49,357 on December 31, ~~2021.~~2022.

We have experienced cumulative losses of ~~$272,968~~$298,675 from inception (August 11, 2011) through ~~September 30, 2022~~March 31, 2023 and have a stockholders’ equity of ~~$88,946~~$72,030 on ~~September 30, 2022.~~March 31, 2023. In addition, we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future. However, we believe that our sources of liquidity and capital resources will be sufficient to meet our business needs for at least the next twelve months.

Since inception, we have financed our operations primarily through private placements and public offerings of our common stock and warrants to purchase shares of our common stock, ~~the exercise of existing warrants and options, and~~ ~~credit facility,~~receiving aggregate net proceeds totaling ~~$251,494~~$227,971,000 and a credit facility of $23,786,000 as of ~~September 30, 2022.~~March 31, 2023.

On February 1, 2021, we entered into securities purchase agreements with institutional accredited investors relating to an offering with respect to the sale of an aggregate of 3,278,688 shares of Common Stock, at a purchase price of $21.35 per share. The aggregate gross proceeds were approximately $70,000.

On February 28, 2022, we entered into a securities purchase agreement with institutional investors, pursuant to which we agreed to issue and sell to the investors in a registered direct offering priced at-the-market under Nasdaq rules an aggregate of 4,674,454 shares of our common stock, par value $0.0001 per share, and pre-funded warrants to purchase an aggregate of 667,559 shares of our common stock. Each share was sold at an offering price of $7.49 per share, and each pre-funded warrant was sold at an offering price of $7.4899, for aggregate gross proceeds of approximately $40 million before deducting the offering expenses. In addition, the investors have executed lock up agreements agreeing to a lock up period of three days.

On October 22, 2021, we entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), as agent, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $50 million from time to time through Cowen. As of ~~June 30, 2022,~~March 31, 2023, we ~~have not conducted any sales through~~sold an aggregate of 73,037 shares of our common stock for aggregate net proceeds of approximately $260,000, pursuant to the Sales ~~Agreement with Cowen.~~Agreement.

Table of Contents

On ~~June 9, 2022 (the “Closing Date”),~~February 1, 2021, we entered into securities purchase agreements with institutional accredited investors relating to an offering with respect to the sale of an aggregate of 3,278,688 shares of Common Stock, at a ~~credit agreement (the “Credit Agreement”)~~purchase price of $21.35 per share. The aggregate gross proceeds were approximately $70,000.

On May 1, 2023, we entered into Purchase Agreements with accredited investors relating to an offering and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock, an aggregate of 7,946 shares of Series B-1 Preferred Stock, and an aggregate of 150 shares of Series B-2 Preferred Stock, at a purchase price of $1,000 for each share of Preferred Stock. Certain of our executive officers and directors purchased shares of Series B-2 Preferred Stock in the Offering. On May 5, 2023, we entered into Purchase Agreement with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock, at a purchase price of $1,000 for each share of Preferred Stock. As a result of the sale of the Preferred Stock, the aggregate gross proceeds to us from the Offering are approximately $15.4 million.

On May 1, 2023, we entered into the LSA, with the ~~Lender. The Credit Agreement~~Lenders, which provides for a ~~five-year senior~~four-year secured credit facility in an aggregate principal amount of up to ~~$50~~$40 million, of which ~~$25~~$30 million was made available on the ~~Closing Date (the “Initial Commitment Amount”)~~closing date and up to ~~$25~~$10 million may be made available on the later of July 1, 2023 or ~~prior to June 30,~~the date the Lender approves the issuance of the Discretionary Tranche. On May 1, 2023, ~~subject to certain revenue requirements (the “Delayed Draw Commitment Amount”). On the Closing Date,~~ we closed on the Initial ~~Commitment Amount,~~Tranche, less certain fees and ~~expenses. If, until the maturity date~~expenses payable to or on behalf of the ~~Loan Facility, our net revenue does not equal or exceed~~Lenders. As a result of the ~~applicable amount for such period as set in~~execution of the LSA and the funding of the Initial Tranche, the Company satisfied its prior Credit Agreement it previously executed with OrbiMed, on June 9, 2022 and terminated the Credit Agreement then we shall repay in equal monthly installments the outstanding principal amount of the Loan Facility During the term of the Loan Facility, interest payable in cash by us shall accrue on any outstanding balance due. We will pay certain fees with respect to the Loan Facility, including an upfront fee, an unused fee on the undrawn portion of the Loan Facility, an administration fee, a repayment premium and an exit fee, as well as certain other fees and expenses of the Lender. We agreed to issue the Lender a warrant to purchase up to 226,586 shares of our common stock, at an exercise price of $6.62 per share, which shall have a term of 7 years from the issuance date. In the event we are eligible to draw the Delayed Draw Commitment Amount, we agreed to issue the Lender an additional warrant, with a term of 7 years from the issuance date, to purchase up to 6% of the Delayed Draw Commitment Amount based on a 10 day volume weighted average price of our common stock with an exercise price equal to the Volume Weighted Average Price.Orbimed.

Management believes that the proceeds from the prior private placement and the Loan Facility and the funds we may draw down from the Sales Agreement, combined with our cash on hand and short-term investments are sufficient to meet our obligations as they come due for at least a period of twelve months from the date of the issuance of these unaudited condensed consolidated financial statements. As a result, we have resolved to remove the going concern note from our financial statements. There are no assurances, however, that we will be able to obtain an adequate level of financial resources that are required for the long-term development and commercialization of our product offering.

As such, we have a significant present need for capital. If we are unable to scale up our commercial launch of our products or meet our commercial sales targets (or if we are unable to generate any revenue at all), and if we are unable to obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our business plans and our business might fail.

Additionally, readers are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. Should this occur, we will need to seek additional capital earlier than anticipated in order to fund (1) further development and, if needed (2) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch Dario, DarioEngage and Dario Intelligence, (3) expenses which will be required in order to expand manufacturing of our products, (4) sales and marketing efforts and (5) general working capital. Such funding may be unavailable to us on acceptable terms, or at all. Our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead to the failure of our company. This would particularly be the case if we are unable to commercially distribute our products and services in the jurisdictions and in the timeframes we expect.

Table of Contents

Cash Flows (dollar amounts in thousands)

The following table sets forth selected cash flow information for the periods indicated:


	September 30,		March 31,
	2022	2021	2023	2022
	$	$	$	$
Cash used in operating activities:	(39,904,000)	(35,273,000)	(4,757,000)	(18,094,000)
Cash used in investing activities:	(514,000)	(7,690,000)	(4,362,000)	(181,000)
Cash provided by financing activities:	61,675,000	65,766,000	(1,389,000)	38,023,000
	21,257,000	22,803,000	(10,508,000)	19,748,000

~~Table of Contents~~

Net cash used in operating activities

Net cash used in operating activities was ~~$39,904~~$4,757,000 for the ~~nine~~three months ended ~~September 30, 2022 an increase~~March 31, 2023 a decrease of ~~13.1%~~73.7% compared to ~~$35,273~~$18,094,000 used in operations for the same period in ~~2021.~~2022. Cash used in operations ~~increased~~decreased mainly due to the ~~increase~~decrease in our operating activities.

Net cash used in investing activities

Net cash used ~~for~~in investing activities was ~~$514~~$4,362,000 for the ~~nine~~three months ended ~~September 30, 2022, a decrease of $7,176~~March 31, 2023 compared to ~~$7,690 for~~$181,000 net cash used in investing activities during the same period in ~~2021. Cash used for investing activities decreased mainly due to the reduction~~2022. The increase is a result of our investment in ~~acquisition activities compared to the payments made as part of the acquisition of Upright and PsyInnovations Inc. during the nine months ended September 30, 2021.~~short-term investments.

Net cash ~~provided by~~used in financing activities

Net cash ~~provided by~~used in financing activities was ~~$61,675~~$1,389,000 for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 compared to ~~$65,766~~$38,023,000 net cash provided by financing activities during the same period in ~~2021.~~2022. The decrease results from the repayment of our loan compared to proceeds from the issuance of common stock and prefunded warrants in the three months ended March 31, 2022.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Report, our Chief Executive Officer and Chief Financial Officer, or the Certifying Officers, conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a–15(e) and 15d–15(e) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act“, the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”). Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officers, to allow timely decisions regarding required disclosures.

Based on their evaluation, the Certifying Officers concluded that, as of ~~September 30, 2022,~~March 31, 2023, our disclosure controls and procedures were designed at a reasonable assurance level and were therefore effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended ~~September 30, 2022,~~March 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Limitations on the Effectiveness of Internal Controls

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

~~Table of Contents~~

PART II- OTHER INFORMATION

Item 1A. Risk Factors.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our ~~2021~~2022 Annual Report and in our Quarterly Report, which could materially affect our business, financial condition, or future results.

There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~202~~1,2022, except as noted below.

Currently, our revenues are concentrated with two major customers, Sanofi, and a national health plan, and our revenues may decrease significantly if we were to lose our major customers.

Due to our limited operating history, we have a limited customer base and have depended on a major customer, Sanofi, for a significant portion of our revenue. On February 8, 2022, we entered into an exclusive preferred partner, co-promotion, development collaboration and license agreement for a term of five (5) years (the “Exclusive Agreement”) with Sanofi. Pursuant to the Exclusive Agreement, we will provide a license to access and use certain Company data. As of ~~September 30, 2022,~~March 31, 2023, our major customer accounted for 27.9%44.4% of our accounts receivable balance and, for the ~~nine and three month periods~~three-month period ended ~~September 30, 2022,~~March 31, 2023, Sanofi accounted for ~~34.7% and~~ ~~19.7%, respectively,~~42.2% of our ~~revenue in the relevant periods.~~revenue. If Sanofi were to terminate the Exclusive Agreement, or if we fail to adequately perform under the Exclusive Agreement, and if we are unable to diversify our customer base, our revenue could decline, and our results of operations could be adversely affected.

In addition, in October 2021, we entered into a master services agreement with a national health plan, which provided for various projects that may be undertaken by us at the direction of the national health plan customer. As of ~~September 30, 2022,~~March 31, 2023, the national health plan customer accounted for ~~39.3%~~13.1% of our accounts receivable balance and, for the ~~nine and three month periods~~three-month period ended ~~September 30, 2022,~~March 31, 2023, they accounted for ~~8.5% and 26.9%, respectively,~~10.0% of our ~~revenue in the relevant periods.~~revenue. During ~~these periods,~~this period, these revenues were as a result of a specific project that we were assigned to complete for this particular customer. There is no guarantee that the national health plan customer will continue to assign us projects under the master services agreement in the future and we may not realize any significant revenues, if at all, if we are not assigned such projects. If we are unable to realize any additional revenues from our master services agreement with the national health plan customer, our revenue could decline, and our results of operations could be adversely affected.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three month period ended ~~September 30, 2022,~~March 31, 2023, we issued an aggregate of ~~8,941~~75,436 shares of the Company’s common stock to certain of our service providers as compensation in lieu of cash compensation owed to them for services rendered.

~~In addition, on September 20, 2022, we entered into an exchange agreement with a certain preferred stockholder to exchange 885 shares~~12

Table of ~~our Series A-1 Preferred Stock for 308,711 shares of our common stock.~~Contents

We claimed exemption from registration under the Securities Act of 1933, as amended, or the Securities Act, for the foregoing transactions under Section 4(a)(2) of the Securities Act.

~~Table of Contents~~

Item 6. Exhibits.

No.		Description of Exhibit
3.1		Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.2		Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.3		Certificate of Designation of Preferences, Rights and Limitations of Series B-2 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
3.4		Certificate of Designation of Preferences, Rights and Limitations of Series B-3 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
4.1		Form of Warrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.1		Form of Securities Purchase Agreement for Series B, Series B-1, and Series B-2 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.2		Loan and Security Agreement, dated May 1, 2023, by and among the Company, as borrower, and Avenue Venture Opportunities Fund II, L.P., as lender (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.3		Form of Preferred Agreement with Series A-1 Convertible Preferred Stockholders (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
10.4		Form of Securities Purchase Agreement for Series B-3 Preferred Stock (incorporated by reference to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2023).
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.
101.1*		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~September 30, 2022,~~March 31, 2023, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Statements of Changes in Stockholders’ Deficiency, (iv) Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail.
104		Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101).

*Filed herewith.

**Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~November 14, 2022~~May 11, 2023		DarioHealth Corp.

	By:	/s/ Erez Raphael
		Name:	Erez Raphael
		Title:	Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Zvi Ben David
		Name:	Zvi Ben David
		Title:	Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer)


	Nine Months Ended September 30,
	(in thousands)
	2022		2021		$ Change
Net Loss Reconciliation
Net loss - as reported	$	(49,576)	$	(55,175)	$	5,599

Adjustments
Depreciation expense		243		202		41
Inventory step up amortization		—		985		(985)
Amortization of acquired technology and brand		3,224		2,396		828
Other financial expenses, net		1,775		346		1,429
Income Tax		1		—		1

EBITDA		(44,333)		(51,246)		6,913

Acquisition costs		—		880		(880)
Earn-out remeasurement		945		—		945
Stock-based compensation expenses		13,898		18,670		(4,772)

Non-GAAP adjusted loss	$	(29,490)	$	(31,696)	$	2,206

Amortization

period (Years)

Technology